Novel genomic loci influence patterns of structural covariance in the human 1 2 brain

3

4 Junhao Wen^{1,2*}, Ilya M. Nasrallah^{2,3}, Ahmed Abdulkadir², Theodore D. Satterthwaite^{2,4}, Zhijian Yang²,

- 5 Guray Erus², Timothy Robert-Fitzgerald⁵, Ashish Singh², Aristeidis Sotiras⁶, Aleix Boquet-Pujadas⁷,
- Elizabeth Mamourian², Jimit Doshi², Yuhan Cui², Dhivya Srinivasan², Ioanna Skampardoni², Jiong 6
- 7 Chen², Gyujoon Hwang², Mark Bergman², Jingxuan Bao⁸, Yogasudha Veturi⁹, Zhen Zhou², Shu Yang⁸, Paola Dazzan¹⁰, Rene S. Kahn¹¹, Hugo G. Schnack¹², Marcus V. Zanetti¹³, Eva Meisenzahl¹⁴, Geraldo F.
- 8 Busatto¹³, Benedicto Crespo-Facorro¹⁵, Christos Pantelis¹⁶, Stephen J. Wood¹⁷, Chuanjun Zhuo¹⁸, Russell 9
- T. Shinohara^{2,5}, Ruben C. Gur⁴, Raquel E. Gur⁴, Nikolaos Koutsouleris¹⁹, Daniel H. Wolf^{2,4}, Andrew J. 10
- Saykin²⁰, Marylyn D. Ritchie⁹, Li Shen⁸, Paul M. Thompson²¹, Olivier Colliot²², Katharina Wittfeld²³, 11
- Hans J. Grabe²³, Duygu Tosun²⁴, Murat Bilgel²⁵, Yang An²⁵, Daniel S. Marcus²⁶, Pamela LaMontagne²⁶, 12
- Susan R. Heckbert²⁷, Thomas R. Austin²⁷, Lenore J. Launer²⁸, Mark Espeland²⁹, Colin L Masters³⁰, Paul 13
- Maruff³⁰, Jurgen Fripp³¹, Sterling C. Johnson³², John C. Morris³³, Marilyn S. Albert³⁴, R. Nick Bryan³, 14
- Susan M. Resnick²⁵, Yong Fan², Mohamad Habes³⁵, David Wolk^{2,36}, Haochang Shou^{2,5}, and Christos 15
- Davatzikos^{2*}, for the iSTAGING, the BLSA, the BIOCARD, the PHENOM, the ADNI studies, and the 16 17 AI4AD consortium
- 18
- 19 ¹Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School of
- 20 Medicine of USC, University of Southern California, Los Angeles, California, USA.
- 21 ²Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for Biomedical Image Computing and
- 22 23 Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- ³Department of Radiology, University of Pennsylvania, Philadelphia, USA.
- 24 ⁴Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 25 ⁵Penn Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology, and Informatics,
- 26 Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 27 ⁶Department of Radiology and Institute for Informatics, Washington University School of Medicine, St. Louis, USA
- 28 ⁷Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- 29 ⁸Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine, 30 Philadelphia, USA
- 31 ⁹Department of Genetics and Institute for Biomedical Informatics, Perelman School of Medicine, University of 32 33 Pennsylvania, Philadelphia, PA, USA
- ¹⁰Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College
- 34 London, London, UK
- 35 ¹¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
- 36 ¹²Department of Psychiatry, University Medical Center Utrecht, Utrecht, Netherlands
- 37 ¹³Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
- 38 ¹⁴ Department of Psychiatry and Psychotherapy, HHU Düsseldorf, Germany
- 39 ¹⁵Hospital Universitario Virgen del Rocio, University of Sevilla-IBIS; IDIVAL-CIBERSAM, Sevilla, Spain
- 40 ¹⁶Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health,
- 41 Carlton South, Australia
- 42 ¹⁷Orygen and the Centre for Youth Mental Health, University of Melbourne; and the School of Psychology,
- 43 University of Birmingham, UK
- 44 ¹⁸key Laboratory of Real Tine Tracing of Brain Circuits in Psychiatry and Neurology (RTBCPN-Lab), Nankai
- 45 University Affiliated Tianjin Fourth Center Hospital; Department of Psychiatry, Tianjin Medical University, Tianjin, 46 China
- 47 ¹⁹Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University, Munich, Germany
- 48 ²⁰Radiology and Imaging Sciences, Center for Neuroimaging, Department of Radiology and Imaging Sciences,
- 49 Indiana Alzheimer's Disease Research Center and the Melvin and Bren Simon Cancer Center, Indiana University
- 50 School of Medicine, Indianapolis
- 51 ²¹Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of
- 52 Medicine of USC, University of Southern California, Marina del Rey, California

- 53 ²²Sorbonne Université, Institut du Cerveau Paris Brain Institute ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la
- 54 Pitié Salpêtrière, F-75013, Paris, France
- ⁵⁵²³Department of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), University
- 56 Medicine Greifswald, Germany
- 57 ²⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
- 58 ²⁵Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, USA
- ²⁶Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
- ²⁷Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA,
 USA
- 62 ²⁸Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA
- ²⁹Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem,
 North Carolina, USA
- ³⁰Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- ³¹CSIRO Health and Biosecurity, Australian e-Health Research Centre CSIRO, Brisbane, Queensland, Australia
- ³²Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison,
 Wisconsin, USA
- ³³Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
- ³⁴Department of Neurology, Johns Hopkins University School of Medicine, USA
- ³⁵Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at
- 72 San Antonio, San Antonio, USA
- 73 ³⁶Department of Neurology and Penn Memory Center, University of Pennsylvania, Philadelphia, USA
- 74
- 75 *Corresponding authors:
- 76 Junhao Wen, Ph.D. junhaowe@usc.edu
- 77 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 78 Christos Davatzikos, Ph.D. <u>Christos.Davatzikos@pennmedicine.upenn.edu</u>
- 79 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
- 80
- 81 Word counts: 5002 words

82 Abstract

83 Normal and pathologic neurobiological processes influence brain morphology in coordinated 84 ways that give rise to patterns of structural covariance (PSC) across brain regions and individuals 85 during brain aging and diseases. The genetic underpinnings of these patterns remain largely 86 unknown. We apply a stochastic multivariate factorization method to a diverse population of 87 50,699 individuals (12 studies, 130 sites) and derive data-driven, multi-scale PSCs of regional 88 brain size. PSCs were significantly correlated with 915 genomic loci in the discovery set, 617 of 89 which are novel, and 72% were independently replicated. Key pathways influencing PSCs 90 involve reelin signaling, apoptosis, neurogenesis, and appendage development, while pathways 91 of breast cancer indicate potential interplays between brain metastasis and PSCs associated with 92 neurodegeneration and dementia. Using support vector machines, multi-scale PSCs effectively 93 derive imaging signatures of several brain diseases. Our results elucidate new genetic and 94 biological underpinnings that influence structural covariance patterns in the human brain. 95

97 Significance statement

- 98 The coordinated patterns of changes in the human brain throughout life, driven by brain
- 99 development, aging, and diseases, remain largely unexplored regarding their underlying genetic
- 100 determinants. This study delineates 2003 multi-scale patterns of structural covariance (PSCs) and
- 101 identifies 617 novel genomic loci, with the mapped genes enriched in biological pathways
- 102 implicated in reelin signaling, apoptosis, neurogenesis, and appendage development. Overall, the
- 103 2003 PSCs provide new genetic insights into understanding human brain morphological changes
- 104 and demonstrate great potential in predicting various neurologic conditions.

105 Introduction

106 Brain structure and function are interrelated via complex networks that operate at multiple scales, 107 ranging from cellular and synaptic processes, such as neural migration, synapse formation, and 108 axon development, to local and broadly connected circuits.¹ Due to a fundamental relationship 109 between activity and structure, many normal and pathologic neurobiological processes, driven by 110 genetic and environmental factors, collectively cause coordinated changes in brain morphology. 111 Structural covariance analyses investigate such coordinated changes by seeking patterns of 112 structural covariation (PSC) across brain regions and individuals.¹ For example, during 113 adolescence, PSCs derived from magnetic resonance imaging (MRI) have been considered to 114 reflect a coordinated cortical remodeling as the brain establishes mature networks of functional specialization.² Structural covariance is not only related to normal brain development or aging 115 116 processes but can also reflect coordinated brain change due to disease. For example, individuals 117 with motor speech dysfunction may develop brain atrophy in Broca's inferior frontal cortex and co-occurring brain atrophy in Wernicke's area of the superior temporal cortex.³ Refer to Fig. 1C 118 119 for an illustrative depiction.

120 The human brain develops, matures, and degenerates in coordinated patterns of structural covariance at the macrostructural level of brain morphology.¹ However, the mechanisms 121 122 underlying structural covariance are still unclear, and their genetic underpinnings are largely 123 unknown. We hypothesized that brain morphology was driven by multiple genes (i.e., polygenic) 124 collectively operating on different brain areas (i.e., pleiotropic), resulting in connected networks 125 covaried by normal aging and various disease-related processes. Along the causal pathway from 126 underlying genetics to brain morphological changes, we sought to elucidate which genetic 127 underpinnings (e.g., genes), biological processes (e.g., neurogenesis), cellular components (e.g.,

nuclear membrane), molecular functions (e.g., nucleic acid binding), and neuropathological
processes (e.g., Alzheimer's disease) might influence the formation, development, and changes
of structural covariance patterns in the human brain.

Previous neuroimaging genome-wide association studies (GWAS)^{4,5} have partially 131 132 investigated the abovementioned questions and expanded our understanding of the genetic 133 architecture of the human brain. However, they focused on conventional neuroanatomical 134 regions of interest (ROI) instead of data-driven PSCs. In brain imaging research, prior studies 135 have applied structural covariance analysis to elucidate underlying coordinated morphological changes in brain aging and various brain diseases,¹ but have had several limitations. They often 136 137 relied on pre-defined neuroanatomical ROIs to construct inter- and intra-individual structural 138 covariance networks. These *a priori* ROIs might not optimally reflect the molecular-functional 139 characteristics of the brain. In addition, most population-based studies have investigated brain 140 structural covariance within a relatively limited scope, such as within relatively small samples, over a relatively narrow age window (e.g., adolescence²), within a single disease (e.g., 141 142 Parkinson's disease⁶), or within datasets lacking sufficient diversity in cohort characteristics or 143 MRI scanner protocols. These have been imposed, in part, by limitations in both available cohort 144 size and in the algorithmic implementation of structural covariance analysis, which has been 145 computationally restricted to modest sample sizes when investigated at full image resolution. 146 Lastly, prior studies have examined brain structural covariance at a single fixed ROI 147 resolution/scale/granularity. While the optimal scale is unknown and may differ by the question 148 of interest, the highly complex organization of the human brain may demonstrate structural covariance patterns that span multiple scales.^{7,8} 149

150 To address this gap, we modified our previously proposed orthogonally projective non-151 negative matrix factorization (opNMF⁹) to its stochastic counterpart, sopNMF. This adaptation 152 allowed us to train the model iteratively on large-scale neuroimaging datasets with a pre-defined 153 number of PSCs (C). Non-negative matrix factorization has gained significant attention in 154 neuroimaging due to its ability to reduce complex data into a sparse, part-based brain 155 representation by projection onto a relatively small number of components (the PSCs). NMF has 156 been shown to substantially improve interpretability and reproducibility compared to other 157 unsupervised methods, such as PCA and ICA, thanks to the non-negative constraint that 158 produces parcellation-like decompositions of complex signals. Our opNMF/sopNMF approach 159 imposed an additional orthonormality constraint⁹ (*Equation 1* in **Method 1**), further enhancing 160 sparsity and facilitating clinical interpretability. In our previous work, we applied the opNMF 161 method to 934 youths ages 8–20 to depict the coordinated growth of structural brain networks 162 during adolescence – a period characterized by extensive remodeling of the human cortex to accommodate the rapid expansion of the behavioral repertoire². Remarkably, this study revealed 163 164 PSCs that exhibited a cortical organization closely aligned with established functional brain 165 networks, such as the well-known 7-network functional parcellation proposed by Yeo et al^{10} . 166 Notably, this alignment emerged without prior assumptions, was data-driven and hypothesis-167 free, and potentially reflected underlying neurobiological processes related to brain development 168 and aging. Herein, we used large-scale neuroimaging data to investigate the underlying genetic 169 determinant influencing such changes in structural covariance patterns in the human brain. 170 We examined structural covariance of regional cortical and subcortical volume in the 171 human brain using MRI from a diverse population of 50,699 people from 12 studies, 130 sites,

and 12 countries, comprised of cognitively healthy individuals, as well as participants with

173	various diseases/conditions over their lifespan (ages 5 through 97). Herein we present results
174	from coarse to fine scales corresponding to $C = 32, 64, 128, 256, 512$, and 1024. We
175	hypothesized that PSCs at multiple scales could delineate the human brain's multi-factorial and
176	multi-faceted morphological landscape and genetic architecture in healthy and diseased
177	individuals. We examined the associations between these multi-scale PSCs and common genetic
178	variants at different levels (N=8,469,833 SNPs). In total, 617 novel genomic loci were identified;
179	key pathways (e.g., neurogenesis and reelin signaling) contributed to shaping structural
180	covariance patterns in the human brain. In addition, we leveraged PSCs at multiple scales to
181	better derive individualized imaging signatures of several diseases than any single-scale PSCs
182	using support vector machines. All experimental results and the multi-scale PSCs were
183	integrated into the MuSIC (Multi-scale Structural Imaging Covariance) atlas and made publicly
184	accessible through the BRIDGEPORT (BRaIn knowleDGE PORTal) web portal:
185	https://www.cbica.upenn.edu/bridgeport/. Table 1 provides an overview of the abbreviations
186	used in the present study.

Item	Abbreviation	Item	Abbreviation
Pattern of structural covariation	PSC	Independent component analysis	ICA
Genome-wide association study	GWAS	BRaIn knowleDGE PORTal	BRIDGEPORT
Orthogonal projective non-negative matrix factorization	opNMF	Multi-scale Structural Imaging Covariance	MuSIC
Stochastic orthogonal projective non-negative matrix factorization	sopNMF	Machine learning	ML
Principal component analysis	PCA	UK Biobank	UKBB
Imaging-based coordinate SysTem for AGing and NeurodeGenerative diseases	iSTAGING	Psychosis Heterogeneity Evaluated via Dimensional Neuroimaging	PHENOM
Single nucleotide	SNP	Region of interest	ROI
Magnetic resonance imaging	MRI	Automated anatomical labeling	AAL
MUlti-atlas region Segmentation utilizing Ensembles	MUSE	Alzheimer's disease	AD
Spatial PAtterns for REcognition	SPARE	Support vector machine	SVM

Table 1. Abbreviations used in the present study

190 **Results**

191 We summarize this work in three units (I to III) outlined in Fig. 1. In Unit I (Fig. 1A), we 192 present the stochastic orthogonally projective non-negative matrix factorization (sopNMF) 193 algorithm (Method 1), optimized for large-scale multivariate structural covariance analysis. The 194 sopNMF algorithm decomposes large-scale imaging data through online learning to overcome 195 the memory limitations of opNMF. A subgroup of participants with multiple disease diagnoses 196 and healthy controls (ages 5-97, training population, N=4000, **Method 2**) were sampled from the 197 discovery set (N=32,440, Method 2); their MRI underwent a standard imaging processing 198 pipeline (Method 3A). The processed images were then fit to sopNMF to derive the multi-scale 199 PSCs (N=2003) from the loadings of the factorization (Method 1). We incorporate participants 200 with various disease conditions because previous studies have demonstrated that inter-regional 201 correlated patterns (i.e., depicting a network) show variations in healthy and diseased populations, albeit to a differing degree.¹¹ Multi-scale PSCs were extracted across the entire 202 population and statistically harmonized¹² (Method 3B). Unit II (Fig. 1B) investigates the 203 harmonized data for 2003 PSCs (13 PSCs have vanished in this process for C=1024; see Method 204 205 1) in two brain structural covariance analyses. Specifically, we performed i) GWAS (Method 4) 206 that sought to discover associations of PSCs at single nucleotide polymorphism (SNP), gene, or 207 gene set-level; and *ii*) pattern analysis via support vector machine (Method 5) to derive 208 individualized imaging signatures of several brain diseases and conditions. Unit III (Fig. 1C) 209 presents BRIDGEPORT, making these massive analytic resources publicly available to the 210 imaging, genomics, and machine learning communities. 211



213 Figure 1: Study workflow



215 A) Unit I: the stochastic orthogonally projective non-negative matrix factorization (sopNMF) algorithm was applied to a large, disease-diverse population to derive multi-scale patterns of 216 217 structural covariance (PSC) at different scales (C=32, 64, 128, 256, 512, and 1024; C represents 218 the number of PSCs). B) Unit II: two types of analyses were performed in this study: Genome-219 wide association studies (GWAS) relate each of the PSCs (N=2003) to common genetic variants; 220 pattern analysis via machine learning demonstrates the utility of the multi-scale PSCs in deriving 221 individualized imaging signatures of various brain pathologies. C) Unit III: BRIDGEPORT is a

- 222 web portal that makes all resources publicly available for dissemination. As an illustration, a 223
- Manhattan plot for PSC (C64-3, the third PSC of the C64 atlas) and its 3D brain map are 224 displayed.
- 225

226 Patterns of structural covariance via stochastic orthogonally projective non-negative

227 matrix factorization

228 We first validated the sopNMF algorithm by showing that it converged to the global minimum of 229 the factorization problem using the comparison population (N=800, Method 2). The sopNMF 230 algorithm achieved similar reconstruction loss and sparsity as opNMF but at reduced memory 231 demand (Supplementary eFigure 1). The lower memory requirements of sopNMF made it 232 possible to generate multi-scale PSCs by jointly factorizing 4000 MRIs in the training 233 population. The results of the algorithm were robust and obtained a high reproducibility index 234 (RI) (Supplementary eMethod 2) in several reproducibility analyses: split-sample analysis (RI 235 $= 0.76 \pm 0.27$), split-sex analysis (RI = 0.79 \pm 0.27), and leave-one-site-out analysis (RI = 0.65-236 0.78 for C32 PSCs) (Supplementary eFigure 2). We then extracted the multi-scale PSCs in the 237 discovery set (N=32,440) and the replication set (N=18,259, Method 2) for Unit II. These PSCs 238 succinctly capture underlying neurobiological processes across the lifespan, including the effects 239 of typical aging processes and various brain diseases. In addition, the multi-scale representation 240 constructs a hierarchy of brain structure networks (e.g., PSCs in cerebellum regions), which 241 models the human brain in a multi-scale topology.^{7,13} 242 243 Patterns of structural covariance are highly heritable

The multi-scale PSCs are highly heritable ($0.05 < h^2 < 0.78$), showing high SNP-based heritability estimates (h^2) (**Method 4B**) for the discovery set (**Fig. 2**). Specifically, the h^2 estimate was 0.49±0.10, 0.39±0.14, 0.29±0.15, 0.25±0.15, 0.27±0.15, 0.31±0.15 for scales *C*=32, 64, 128, 256, 512 and 1024 of the PSCs, respectively. The Pearson correlation coefficient between the two independent estimates of h^2 was r = 0.94 (p-value < 10⁻⁶, between the discovery and replication sets) in the UK Biobank (UKBB) data. The scatter plot of the two sets of h^2 estimates is shown in **Supplementary eFigure 3**. The h^2 estimates and p-values for all PSCs are detailed in

Supplementary eFile 1 (discovery set) and eFile 2 (replication set). Our results confirm that brain
 structure is heritable to a large extent and identify the spatial distribution of the most highly
 heritable regions of the brain (e.g., subcortical gray matter structures and cerebellum regions).¹⁴

Figure 2: Patterns of structural covariance are highly heritable in the human brain.



256

Patterns of structural covariance (PSCs) of the human brain are highly heritable. The SNP-based
heritability estimates are calculated for the multi-scale PSCs at different scales (*C*). PSCs
surviving Bonferroni correction for multiple comparisons are depicted in color in the Manhattan
plots (gray otherwise). Each PSC's heritability estimate (h2) was projected onto the 3D image
space to show a statistical map of the brain at each scale *C*. The dotted line indicates each scale's
top 10% of most heritable PSCs.

263

264 **617 novel genomic loci of patterns of structural covariance**

- 265 We discovered genomic locus-PSC pairwise associations (Method 4C, Supplementary
- **eMethod 5**) within the discovery set and then independently replicated these associations on the
- 267 replication set. We found that 915 genomic loci had 3791 loci-PSC pairwise significant
- associations with 924 PSCs after Bonferroni correction (Method 4G) for the number of PSCs (p-
- value threshold per scale: $10.3 > -\log_{10}[p-value] > 8.8$) (Supplementary eFile 3, and Fig. 3A).
- 270 Our results showed that the formation of these PSCs is largely polygenic; the associated SNPs
- 271 might play a pleiotropic role in shaping these networks.

272 Compared to previous literature, out of the 915 genomic loci, the multi-scale PSCs 273 identified 617 novel genomic loci not previously associated with any traits or phenotypes in the GWAS Catalog¹⁵ (Supplementary eFile 4, Fig. 3B, query date: April 5th, 2023). These novel 274 275 associations might indicate subtle neurobiological processes that are captured thanks to the 276 biologically relevant structural covariance expressed by sopNMF. The multi-scale PSCs 277 identified many novel associations by constraining this comparison to previous neuroimaging 278 GWAS^{12,13} using T1w MRI-derived phenotypes (e.g., regions of interest from conventional brain 279 atlases) (Fig 3B, Supplementary eTable 3, eFile 5, 6, and 7). 280 Our UKBB replication set analysis (Method 4H) demonstrated that 3638 (96%) exact 281 genomic locus-PSC associations were replicated at nominal significance $(-\log_{10}[p-value] > 1.31)$, 282 2705(72%) of which were significant after correction for multiple comparisons (Method 4G, -283 \log_{10} [p-value] > 4.27). We present this validation in **Supplementary eFile 8** from the replication 284 set. The summary statistics, Manhattan, and QQ plots derived from the combined population 285 (*N*=33,541) are presented in BRIDGEPORT. 286 In addition to the abovementioned replication analyses, we also performed several 287 sensitivity analyses (Supplementary eFigure 4a). We used the GWAS results (233 significant 288 SNPs in 5 genomic loci) of the first PSC in C32 (C32_1) from the UKBB discovery set to 289 demonstrate this. First, we replicated all the 233 significant SNPs in 5 genomic loci both at the 290 nominal level $(-\log_{10}[p-value] > 1.31)$, and the Bonferroni corrected p-value threshold $(-\log_{10}[p-value] > 1.31)$ 291 value] > 3.67) using the combined discovery and replication sets (N=33,541) (Supplementary 292 eFigure 4b), the 20,438 4ticipants with all ancestries in the discovery set (Supplementary 293 eFigure 4c), and the 16,743 participants in the discovery set with four additional imaging-related 294 covariates (3 parameters for the brain position in the lateral, longitudinal, and transverse

295	directions, and 1 parameter for the head motion from fMRI) (Supplementary eFigure 4d).
296	While replicating the results in 2386 participants with non-European ancestries, we only
297	replicated 41 SNPs (17.6%), passing the nominal significant threshold (Supplementary eFigure
298	4e). Finally, only 14 SNPs (6.4%) were replicated when replicating the results using 1481 whole-
299	genome sequencing (WGS) data from ADNI consolidated by the AI4AD consortium ¹⁶
300	(Supplementary eFigure 4f). The low replication rates in other ancestries and independent
301	disease-specific populations are expected due to population stratification, disease-specific
302	effects, and reduced sample sizes. This further emphasizes the urge to enrich and diversify
303	genetic research with non-European ancestries and disease-specific populations.
304	
305	
306	
307	
308	
309	
310	
311	

- 312 Figure 3: Patterns of structural covariance highlight novel genomic loci and pathways that
- 313 shape the human brain.



314

315 A) Patterns of structural covariance (PSC) in the human brain are polygenic: the number of 316 genomic loci of each PSC is projected onto the image space to show a statistical brain map 317 characterized by the number (C) of PSCs. In addition, common genetic variants exert pleiotropic 318 effects on the PSCs: circular plots showed the number of associated PSCs (histograms in blue 319 color) of each genomic loci over the entire autosomal chromosome (1-22). The histogram was 320 plotted for the number of PSCs for each genomic locus in the circular plots. **B**) Novel genomic loci revealed by the multi-scale PSCs compared to previous findings from the GWAS Catalog,¹⁵ 321 T1-weighted MRI GWAS^{4,5}, and the AAL atlas regions of interest. The green bar indicates the 322 323 617 novel genomic loci not previously associated with any clinical traits in GWAS Catalog; the 324 black bar presents the loci identified in other studies that overlap (grey bar for loci in linkage 325 disequilibrium) with the loci from our results; the yellow bar indicates the unique loci in other 326 studies. C) Pathway enrichment analysis highlights six unique biological pathways and

functional categories (after Bonferroni correction for 16,768 gene sets and the number of PSCs)
 that might influence the changes of PSCs. DSCAM: Down syndrome cell adhesion molecule.

330

331 Gene set enrichment analysis highlights pathways that shape patterns of structural

332 covariance

333 For gene-level associations (Method 4D), we discovered that 164 genes had 2489 gene-PSC

pairwise associations with 445 PSCs after Bonferroni correction for the number of genes and

335 PSCs (p-value threshold: $8.6 > -\log_{10}[p-value] > 7.1$) (Supplementary eFile 9).

Based on these gene-level p-values, we performed hypothesis-free gene set pathway

analysis using MAGMA¹⁷(**Method 4E**): a more stringent correction for multiple comparisons

338 was performed than the prioritized gene set enrichment analysis using GENE2FUN from FUMA

339 (Method 4F and Fig. 4). We identified that six gene set pathways had 18 gene set-PSC pairwise

340 associations with 17 PSCs after Bonferroni correction for the number of gene sets and PSCs

341 (N=16,768 and C from 32 to 1024, p-value threshold: $8.54 > -\log_{10}[p-value] > 7.03$) (**Fig. 3C**,

342 **Supplementary eFile 10**). These gene sets imply critical biological and molecular pathways that

343 might shape brain morphological changes and development. The reelin signaling pathway

344 regulates neuronal migration, dendritic growth, branching, spine formation, synaptogenesis, and

345 synaptic plasticity.¹⁸ The appendage morphogenesis and development pathways indicate how the

anatomical structures of appendages are generated, organized, and progressed over time, often

related to the cell adhesion pathway. These pathways elucidate how cells or tissues can be

348 organized to create a complex structure like the human brain.¹⁹ In addition, the integral

349 component of the cytoplasmic side of the endoplasmic reticulum membrane is thought to form a

350 continuous network of tubules and cisternae extending throughout neuronal dendrites and

351 axons.²⁰ The DSCAM (Down syndrome cell adhesion molecule) pathway likely functions as a

352 cell surface receptor mediating axon pathfinding. Related proteins are involved in hemophilic intercellular interactions.²¹ Lastly, Nikolsky et al.²² defined genes from the breast cancer 20Q11 353 354 amplicon pathway that were involved in the brain might indicate the brain metastasis of breast cancer, which is usually a late event with deleterious effects on the prognosis.²³ In addition, 355 356 previous findings^{24,25} revealed an inverse relationship between Alzheimer's disease and breast 357 cancer, which might indicate a close genetic relationship between the disease and brain 358 morphological changes mainly affecting the entorhinal cortex and hippocampus (PSC: C128_3 359 in **Fig. 4**).

360

361 Illustrations of genetic loci and pathways forming two patterns of structural covariance 362 To illustrate how underlying genetic underpinnings might form a specific PSC, we showcased 363 two PSCs: C32_4 for the superior cerebellum and C128_3 for the hippocampus-entorhinal 364 cortex. The two PSCs were highly heritable and polygenic in our GWAS using the entire UKBB data (Fig. 4, N=33,541). We used the FUMA²⁶ online platform to perform SNP2GENE for 365 366 annotating the mapped genes and GENE2FUNC for prioritized gene set enrichment analyses 367 (Method 4F). The superior cerebellum PSC was associated with genomic loci that can be 368 mapped to 85 genes, which were enriched in many biological pathways, including psychiatric 369 disorders, biological processes, molecular functions, and cellular components (e.g., apoptotic 370 process, axon development, cellular morphogenesis, neurogenesis, and neuro differentiation). 371 For example, apoptosis – the regulated cell destruction – is a complicated process that is highly 372 involved in the development and maturation of the human brain and neurodegenerative diseases.²⁷ Neurogenesis – new neuron formation – is crucial when an embryo develops and 373

374	continues in specific brain regions throughout the lifespan. ²⁸ All significant results of this
375	prioritized gene set enrichment analysis are presented in Supplementary eFile 11.
376	For the hippocampus-entorhinal cortex PSC, we mapped 45 genes enriched in gene sets
377	defined from GWAS Catalog, including Alzheimer's disease and brain volume derived from
378	hippocampal regions. The hippocampus and medial temporal lobe have been robust hallmarks of
379	Alzheimer's disease. ²⁹ In addition, these genes were enriched in the breast cancer 20Q11
380	amplicon pathway ²² and the pathway of metastatic breast cancer tumors ³⁰ , which might indicate
381	a specific distribution of brain metastases: the vulnerability of medial temporal lobe regions to
382	breast cancer, ²³ or highlight an inverse association between Alzheimer's disease and breast
383	cancer. ²⁴ Lastly, the nuclear membrane encloses the cell's nucleus – the chromosomes reside
384	inside – which is critical in cell formation activities related to gene expression and regulation. To
385	further support the overlapping genetic underpinnings between this PSC and Alzheimer's
386	disease, we calculated the genetic correlation ($r_g = -0.28$; p-value=0.01) using GWAS summary
387	statistics from the hippocampus-entorhinal cortex PSC (i.e., 33,541 people of European ancestry)
388	and a previous independent study of Alzheimer's disease ³¹ (i.e., 63,926 people of European
389	ancestry) using LDSC. ³² All significant results of this prioritized gene set enrichment analysis
390	are presented in Supplementary eFile 12.
391	

Figure 4: Illustrations of multiple genetic loci and pathways shaping specific patterns of structural covariance



395

396 We demonstrate how underlying genomic loci and biological pathways might influence the

- 397 formation, development, and changes of two specific PSCs: the 4th PSC of the C32 PSCs
- 398 (C32_4) that resides in the superior part of the cerebellum and the 3rd PSC of the C128 PSCs
- 399 (C128_3) that includes the bilateral hippocampus and entorhinal cortex. We first performed
- 400 SNP2GENE to annotate the mapped genes in the Manhattan plots and then ran GENE2FUNC for

401 the prioritized gene set enrichment analysis (Method 4F). The mapped genes are input genes for 402 prioritized gene set enrichment analyses. The heat map shows the significant gene sets from the 403 GWAS Catalog, curated genes, and gene ontology (GO) that survived the correction for multiple 404 comparisons. We selectively present the schematics for three pathways: apoptosis, neurogenesis, 405 and nuclear membrane function. Several other key pathways are highlighted in bold, and the 3D 406 maps of the two PSCs are presented.

407

408 Multi-scale patterns of structural covariance derive disease-related imaging signatures

- 409 We used the multi-scale PSCs from a diverse population to derive imaging signatures that reflect
- 410 brain development, aging, and the effects of several brain diseases. We investigate the added
- 411 value of the multi-scale PSCs as building blocks of imaging signatures for several brain diseases
- 412 and risk conditions using linear support vector machines (SVM) (**Method 5**).³³ The aim is to
- 413 harness machine learning to drive a clinically interpretable metric for quantifying an individual-

414 level risk to each disease category. To this end, we define the signatures as SPARE-X (Spatial

415 PAtterns for REcognition) indices, where X is the disease. For instance, SPARE-AD captures the

416 degree of expression of an imaging signature of AD-related brain atrophy, which has been shown

417 to offer diagnostic and prognostic value in prior studies.³⁴

418 The most discriminative indices in our samples were SPARE-AD and SPARE-MCI (Fig.

419 **5**, **Supplementary eTable 4a** and **eFigure 5**). C=1024 achieved the best performance for the

420 single-scale analysis (e.g., AD vs. controls; balanced accuracy: 0.90 ± 0.02 ; Cohen's d: 2.50).

421 Multi-scale representations derived imaging signatures that showed the largest effect sizes to

422 classify the patients from the controls (**Fig. 5**) (e.g., AD vs. controls; balanced accuracy:

423 0.92 ± 0.02 ; Cohen's d: 2.61). PSCs obtained better classification performance than both AAL

- 424 (e.g., AD vs. controls; balanced accuracy: 0.82 ± 0.02 ; Cohen's d: 1.81) and voxel-wise regional
- 425 volumetric maps $(RAVENS)^{35}$ (e.g., AD vs. controls; balanced accuracy: 0.85±0.02; Cohen's *d*:
- 426 2.04) (Supplementary eTable 4a and eFigure 5). Our classification results were higher than

427	previous baseline studies ^{36,37} , which provided an open-source framework to objectively and
428	reproducibly evaluate AD classification. Using the same cross-validation procedure and
429	evaluation metric, they reported the highest balanced accuracy of 0.87 ± 0.02 to classify AD from
430	healthy controls. Notably, our experiments followed good practices, employed rigorous cross-
431	validation procedures, and avoided critical methodological flaws, such as data leakage or double-
432	dipping (refer to critical reviews on this topic elsewhere ^{36,38}).
433	To test the robustness of these SPARE indices, we performed leave-one-site-out analyses
434	for SPARE-AD using the combined 2003 PSCs from all scales (Supplementary eTable 4b).
435	Overall, holding the ADNI data out as independent test data resulted in a lower balanced
436	accuracy (0.88 \pm 0.02) compared to the other cases for AIBL (0.95 \pm 0.02) and PENN data
437	(0.95 ± 0.02) . The mean balanced accuracy (0.91 ± 0.02) aligns with the nested cross-validated
438	results using the full sample (Fig. 5).
439	

rigure 5. marviau	anzeu imagi	ng signatur	es baseu on	рацеги апа	1ysis via ma	cinne leart	ung.
C32	C64	C128	C256	C512	C1024	Multi-scale	
1.0 ES=1.52	ES=1.73	ES=1.82	ES=2.08	ES=2.34	ES=2.50	ES=2.61	
AD 0.5					#	*	
1.0 ES = 0.59	ES=0.66	ES=0.76	ES=0.91	ES=1.06	ES=1.12	ES=1.13	
					#	*	
1.0 ES = 0.30	ES=0.41	ES=0.47	ES=0.50	ES=0.62	ES=0.75	ES=0.78	
					#	*	CN
1.0 ES=0.16	ES=0.17	ES=0.15	ES=0.13	ES=0.05	ES=0.13	ES=0.26	
	#					*	PT
≏1.0 ES=0.07	ES=0.19	ES=0.15	ES=0.16	ES=0.24	ES=0.29	ES=0.32	
¹ SD 0.5				\wedge	#	* /	
47 1.0 ES=0.28	ES=0.31	ES=0.30	ES=0.31	ES=0.42	ES=0.46	ES=0.49	
					#	*	
1.0 ES=0.35	ES=0.40	ES=0.33	ES=0.47	ES=0.54	ES=0.59	ES=0.67	
ON 0.5					#	*	
-4 0 4	-4 0 4	-4 0 4	-4 0 4	-4 0 4	-4 0 4	-4 0 4	
			SPARE indic	es			
	$\begin{array}{c} & C32 \\ & C3$	$C32$ C64 $C32$ C64 $C32$ C64 $C32$ ES=1.73 $C32$ ES=1.73 $C32$ ES=1.73 $C32$ ES=1.73 $C32$ ES=1.73 $C32$ ES=1.73 $C32$ ES=0.17 $C32$ ES=0.30 $SC \ge 0.5$ O $C32$ ES=0.16 $SC \ge 0.5$ O $C30$ ES=0.16 $SC \ge 0.5$ O $O1.0$ ES=0.16 $SC \ge 0.5$ O $O1.0$ ES=0.16 $SC \ge 0.5$ O $O1.0$ ES=0.07 $SS = 0.28$ ES=0.31 $SS = 0.35$ O $O1.0$ ES=0.35 $SS = 0.40$ O $O1.0$ $CS = 0.35$ $O1.0$ C	Indicate Indicat Indicat Indicat I	1.0 $C32$ $C64$ $C128$ $C256$ 1.0 $ES=1.52$ $ES=1.73$ $ES=1.82$ $ES=2.08$ 1.0 $ES=0.59$ $ES=0.66$ $ES=0.76$ $ES=0.91$ 1.0 $ES=0.30$ $ES=0.41$ $ES=0.47$ $ES=0.50$ 1.0 $ES=0.16$ $ES=0.17$ $ES=0.15$ $ES=0.13$ 1.0 $ES=0.07$ $ES=0.19$ A A A 1.0 $ES=0.28$ $ES=0.19$ $ES=0.15$ $ES=0.16$ 1.0 $ES=0.28$ $ES=0.31$ $ES=0.30$ $ES=0.31$ 1.0 $ES=0.35$ $ES=0.40$ $ES=0.33$ $ES=0.47$ A	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

440 Figure 5: Individualized imaging signatures based on pattern analysis via machine learning.

442 Imaging signatures (SPARE indices) of brain diseases, derived via supervised machine learning 443 models, are more distinctive when formed from multi-scale PSCs than single-scale PSCs. The 444 kernel density estimate plot depicts the distribution of the patient group (blue) in comparison to 445 the healthy control group (red), reflecting the discriminative power of the diagnosis-specific 446 SPARE (imaging signature) indices. We computed Cohen's d for each SPARE index between 447 groups to present the effect size of its discrimination power. * represents the model with the 448 largest Cohen's d for each SPARE index to separate the control vs. patient groups; # represents 449 the model with the best performance with single-scale PSCs. Our results demonstrate that the 450 multi-scale PSCs generally achieve the largest discriminative effect sizes (ES) (Supplementary 451 eTable 4a). As a reference, Cohen's d of ≥ 0.2 , ≥ 0.5 , and ≥ 0.8 , respectively, refer to small, 452 moderate, and large effect sizes.

453

454 **BRIDGEPORT:** bridging knowledge across patterns of structural covariance, genomics,

455 and clinical phenotypes

456 We integrated our experimental results and the MuSIC atlas into the BRIDGEPORT online web

457 portal. This online tool allows researchers to interactively browse the MuSIC atlas in 3D, query

458 our experimental results via variants or PSCs, and download the GWAS summary statistics for

459 further analyses. In addition, we allow users to search via conventional brain anatomical terms

460 (e.g., the right thalamus proper) by automatically annotating traditional anatomic atlas ROIs,

461 specifically from the MUSE atlas³⁹ (**Supplementary eTable 5**), to MuSIC PSCs based on their

462 degree of overlaps (Supplementary eFigure 6). Open-source software dedicated to image

- 463 processing,³⁹ genetic quality check protocols, MuSIC generation with sopNMF, and machine
- 464 learning³⁶ is also publicly available (see Code Availability for details).

465 **Discussion**

466 The current study investigates patterns of structural covariance in the human brain at multiple 467 scales from a large population of 50,699 people and, importantly, a very diverse cohort allowing 468 us to capture patterns of structural covariance emanating from normal and abnormal brain 469 development and aging, as well as from several brain diseases. Through extensive examination 470 of the genetic architecture of these multi-scale PSCs, we confirmed genetic hits from previous 471 T1-weighted MRI GWAS and, more importantly, identified 617 novel genomic loci and 472 molecular and biological pathways that collectively influence brain morphological changes and 473 development over the lifespan. Using a hypothesis-free, data-driven approach to first derive these 474 PSCs using brain MRIs, we then uncovered their genetic underpinnings and further showed their 475 potential as building blocks to predict various diseases. All experimental results and code are 476 encapsulated and publicly available in BRIDGEPORT for dissemination: 477 https://www.cbica.upenn.edu/bridgeport/, to enable various neuroscience studies to investigate 478 these structural covariance patterns in diverse contexts. Together, the current study highlighted 479 the adoption of machine learning methods in brain imaging genomics and deepened our 480 understanding of the genetic architecture of the human brain.

481 Our findings reveal new insights into genetic underpinnings that influence structural 482 covariance patterns in the human brain. Brain morphological development and changes are 483 largely polygenic and heritable, and previous neuroimaging GWAS has not fully uncovered this 484 genetic landscape. In contrast, genetic variants, as well as environmental, aging, and disease 485 effects, exert pleiotropic effects in shaping morphological changes in different brain regions 486 through specific biological pathways. The mechanisms underlying brain structural covariance are 487 not yet fully understood. They may involve an interplay between common underlying genetic

488 factors, shared susceptibility to aging, and various brain pathologies, which affect brain growth 489 or degeneration in coordinated brain morphological changes.¹ Our data-driven, multi-scale PSCs identify the hierarchical structure of the brain under the principle of structural covariance and are 490 491 associated with genetic factors at different levels, including SNPs, genes, and gene set pathways. 492 These 617 novel genomic loci, as well as those previously identified, collectively shape brain 493 morphological changes through many key biological and molecular pathways. These pathways 494 are widely involved in reelin signaling, apoptotic processes, axonal development, cellular morphogenesis, neurogenesis, and neuro differentiation,^{27,28} which may collectively influence the 495 496 formation of structural covariance patterns in the brain. Strikingly, pathways involved in breast 497 cancer shared overlapping genetic underpinnings evidenced in our MAGMA-based and 498 prioritized (GENE2FUNC) gene set enrichment analyses (Fig. 3C and Fig. 4), which included 499 specific pathways involved in breast cancer and metastatic breast cancer tumors. One previous study showed that common genes might mediate breast cancer metastasis to the brain,²³ and a 500 501 later study further corroborated that the metastatic spread of breast cancer to other organs 502 (including the brain) accelerated during sleep in both mouse and human models.⁴⁰ We further 503 showcased that this brain metastasis of breast cancer might be associated with specific 504 neuropathologic processes, which were captured by PSCs data driven by Alzheimer's disease-505 related neuropathology. For example, the hippocampus-entorhinal cortex PSC (C128_3, Fig. 4) 506 connected the bilateral hippocampus and medial temporal lobe – the salient hallmark of 507 Alzheimer's disease. Our gene set enrichment analysis results further support this claim: the 508 genes were enriched in the gene sets of Alzheimer's disease and breast cancer (Fig. 4). Previous research^{24,25} also found an inverse association between Alzheimer's disease and breast cancer. In 509 510 addition, PSCs from the cerebellum were the most genetically influenced brain regions,

511 consistent with previous neuroimaging GWAS.^{4,5} The cerebral cortex has been thought to largely 512 contribute to the unique mental abilities of humans. However, the cerebellum may also be 513 associated with a much more comprehensive range of complex cognitive functions and brain 514 diseases than initially thought.⁴¹ Our results confirmed that many genetic substrates might 515 support different molecular pathways, resulting in cerebellar functional organization, high-order 516 functions, and dysfunctions in various brain disorders.

517 The current work demonstrates that appropriate machine learning analytics can be used to 518 shed new light on brain imaging genetics. Previous neuroimaging GWAS leveraged multimodal 519 imaging-derived phenotypes from conventional brain atlases^{4,5} (e.g., the AAL atlas). In contrast, 520 multi-scale PSCs are purely data-driven and likely to reflect the dynamics of underlying normal 521 and pathological neurobiological processes giving rise to structural covariance. The diverse 522 training sample from which the PSCs were derived, including healthy and diseased individuals of 523 a wide age range, enriched the diversity of such neurobiological processes influencing the PSCs. 524 In addition, modeling structural covariance at multiple scales (i.e., multi-scale PSCs) indicated 525 that disease effects could be robustly and complementarily identified across scales (Fig. 5), concordant with the paradigm of multi-scale brain modeling.¹³ Imaging signatures of brain 526 527 diseases, derived via supervised machine learning models, were consistently more distinctive 528 when formed from multi-scale PSCs than single-scale PSCs. Multivariate learning techniques 529 have gained significant prominence in neuroimaging and have recently attracted considerable 530 attention in the domain of imaging genomics. These methods have proven valuable for analyzing 531 complex and high-dimensional data, facilitating the exploration of relationships between imaging 532 features and genetic factors. For instance, the MOSTest, a multivariate GWAS approach, 533 preserves correlation structure among phenotypes via permutation on each SNP and derives a

genotype vector for testing the association across all phenotypes⁴². A separate study by Soheili-534 535 Nezhad et al. demonstrated that genetic components obtained through PCA or ICA applied to 536 neuroimaging GWAS summary statistics exhibited greater reproducibility than raw univariate 537 GWAS effect sizes⁴³. A recent study utilized a CNN-based autoencoder to discover new 538 phenotypes and identify numerous novel genetic signals⁴⁴. Despite the effectiveness of these 539 multivariate approaches in GWAS, they typically conduct phenotype engineering before 540 performing GWAS without explicitly incorporating imaging genetic associations during the 541 modeling process. Yang et al. recently conducted a study that employed generative adversarial networks (termed GeneSGAN⁴⁵) to integrate imaging and genetic variations within the modeling 542 543 framework to address this limitation. By incorporating both modalities, their approach aimed to 544 capture the complexity and heterogeneity of disease manifestations.

545 MuSIC – with the strengths of being data-driven, multi-scale, and disease-effect 546 informative – contributes to the century-old quest for a "universal" atlas in brain cartography⁴⁶ 547 and is highly complementary to previously proposed brain atlases. For instance, Chen and colleagues⁴⁷ used a semi-automated fuzzy clustering technique with MRI data from 406 twins 548 549 and parcellated the cortical surface area into a genetic covariance-informative brain atlas; MuSIC was data-driven by structural covariance. Glasser and colleagues⁴⁸ adopted a semi-automated 550 551 parcellation procedure to create a multimodal cortex atlas from 210 healthy individuals. 552 Although this method successfully integrates multimodal information from cortical folding, 553 myelination, and functional connectivity, this semi-automatic approach requires significant 554 resources, some with limited resolution. MuSIC allows flexible, multiple scales for delineating 555 macroscopic brain topology; including patient samples exposes the model to sources of 556 variability that may not be visible in healthy controls. Another pioneering endeavor is the Allen

Brain Atlas project,⁴⁹ whose overarching goals of mapping the human brain to gene expression 557 558 data via existing conventional atlases, identifying local gene expression patterns across the brain 559 in a few individuals, and deepening our understanding of the human brain's differential genetic 560 architecture, are complementary to ours - characterizing the global genetic architecture of the 561 human brain, emphasizing pathogenic variability and morphological heterogeneity. 562 Bridging knowledge across the brain imaging, genomics, and machine learning 563 communities is another pivotal contribution of this work. BRIDGEPORT provides a platform to 564 lower the entry barrier for whole-brain genetic-structural analyses, foster interdisciplinary communication, and advocate for research reproducibility.^{36,50–53} The current study demonstrates 565 566 the broad applicability of this large-scale, multi-omics platform across a spectrum of 567 neurodegenerative and neuropsychiatric diseases. 568 The present study has certain limitations. Firstly, the sopNMF method utilized in brain 569 parcellation considers only imaging structural covariance and overlooks the genetic determinants 570 contributing to forming these structural networks, as indicated by our GWAS findings. 571 Consequently, further investigations are needed to integrate imaging and genetics into brain 572 parcellation. Additionally, it is important to note that our GWAS analyses primarily involved 573 participants of European ancestry. To enhance genetic findings for underrepresented ethnic 574 groups, future studies should prioritize the inclusion of diverse ancestral backgrounds, thereby 575 promoting a more comprehensive understanding of the genetic underpinnings across different 576 populations.

577 Methods

578 Method 1: Structural covariance patterns via stochastic orthogonally projective non-

579 negative matrix factorization

- 580 The sopNMF algorithm is a stochastic approximation built and extended based on $opNMF^{9,54}$.
- 581 We consider a dataset of *n* MR images and *d* voxels per image. We represent the data as a
- 582 matrix X where each column corresponds to a flattened image: $X = [x_1, x_2, ..., x_n], X \in \mathbb{R}^{d \times n}_{\geq 0}$.
- 583 The sopNMF algorithm factorizes X into two low-rank (r) matrices $W \in \mathbb{R}^{d \times r}_{\geq 0}$ and $H \in \mathbb{R}^{r \times n}_{\geq 0}$
- under the constraints of non-negativity and column-orthonormality. Using the Frobenius norm,

*****112

- the loss of this factorization problem can be formulated as
- 586

$$\|\boldsymbol{X} - \boldsymbol{W}\boldsymbol{H}\|_F^2$$

587 subject to
$$H = W^T X$$
, $W \ge 0$ and $W^T W = I$ (1)

where **I** stands for the identity matrix. The columns $w_i \in \mathbb{R}^d$, $||w_i||^2 = 1, \forall i \in \{1, ..., r\}$ of the so-588 589 called component matrix $W = [w_1, w_2, ..., w_r]$ are part-based representations promoting sparsity 590 in data in this lower-dimensional subspace. From this perspective, the loading coefficient matrix 591 **H** represents the importance (weights) of each feature above for a given image. Instead of 592 optimizing the non-convex problem in a batch learning paradigm (i.e., reading all images into memory) as opNMF,⁹ sopNMF subsamples the number of images at each iteration, thereby 593 significantly reducing its memory demand by randomly drawing data batches $X_b \in \mathbb{R}^{d \times b}_{>0}$ of $b \leq b$ 594 595 *n* images (*b* is the batch size; b=32 was used in the current analyses); this is done without 596 replacement so that all data goes through the model once ([n/b]). In this case, the updating rule 597 can be rewritten as

598
$$\boldsymbol{W}_{t+1} = \boldsymbol{W}_t \frac{\left(\boldsymbol{X}_b \boldsymbol{X}_b^T \boldsymbol{W}\right)_t}{\left(\boldsymbol{W} \boldsymbol{W}^T \boldsymbol{X}_b \boldsymbol{X}_b^T \boldsymbol{W}\right)_t} \quad (2)$$

599 We calculate the loss on the entire dataset at the end of each epoch (i.e., the loss is incremental 600 across all batches) with the following expression:

601
$$\sum_{i=1}^{[n/b]} \left\| \boldsymbol{X}_{\boldsymbol{b}_{-}\boldsymbol{i}} - \boldsymbol{W}\boldsymbol{W}^{T}\boldsymbol{X}_{\boldsymbol{b}\boldsymbol{i}} \right\|_{F}^{2} \quad (3)$$

We evaluated the training loss and the sparsity of W at the end of each iteration. Moreover, early

stopping was implemented to improve training efficiency and alleviate overfitting. We

summarize the sopNMF algorithm in **Supplementary Algorithm 1**. An empirical comparison

between sopNMF and opNMF is detailed in **Supplementary eMethod 1**.

606 We applied sopNMF to the training population (N=4000). The component matrix W was

sparse after the algorithm converged with a pre-defined maximum number of epochs (100 by

default) with an early stopping criterion. To build the MuSIC atlas, we clustered each voxel

609 (row-wise) into one of the r features/PSCs as follows:

610
$$\boldsymbol{M}_{j} = \operatorname{argmax}_{k}(\boldsymbol{W}_{j,k}) (4)$$

611 where *M* is a *d*-dimensional vector and $j \in \{1, d\}$. The *j*-th element of *M* equals *k* if $W_{i,k}$ is the

612 maximum value of the *j*-th row. Intuitively, *M* indicates which of the *r* PSCs each voxel belongs

613 to. We finally projected the vector $\mathbf{M} \in \mathbb{R}^{d}_{\geq 0}$ into the original image space to visualize each PSC

of the MuSIC atlas (**Fig. 1**). Of note, 13 PSCs have vanished in this process for C=1024: all 0 for

615 these 13 vectors.

616

617 Method 2: Study population

618 We consolidated a large-scale multimodal consortium (*N*=50,699) consisting of imaging,

619 cognition, and genetic data from 12 studies, 130 sites, and 12 countries (Supplementary eTable

620 1): the Alzheimer's Disease Neuroimaging Initiative⁵⁵ (ADNI) (N=1765); the UK Biobank⁵⁶

621	(UKBB) (N =39,564); the Australian Imaging, Biomarker, and Lifestyle study of aging ⁵⁷ (AIBL)
622	(N=830); the Biomarkers of Cognitive Decline Among Normal Individuals in the Johns Hopkins
623	University ⁵⁸ (BIOCARD) (N=288); the Baltimore Longitudinal Study of Aging ^{59,60} (BLSA)
624	(N=1114); the Coronary Artery Risk Development in Young Adults ⁶¹ (CARDIA) (N=892); the
625	Open Access Series of Imaging Studies ⁶² (OASIS) (N=983), PENN (N=807); the Women's
626	Health Initiative Memory Study ⁶³ (WHIMS) (N=995), the Wisconsin Registry for Alzheimer's
627	Prevention ⁶⁴ (WRAP) (N=116); the Psychosis Heterogeneity (evaluated) via dimEnsional
628	NeurOiMaging ⁶⁵ (PHENOM) (N=2125); and the Autism Brain Imaging Data Exchange ⁶⁶
629	(ABIDE) (<i>N</i> =1220).
630	We present the demographic information of the population under study in
631	Supplementary eTable 1. This large-scale consortium reflects the diversity of MRI scans over
632	different races, disease conditions, and ages over the lifespan. To be concise, we defined four
633	populations or data sets per analysis across the paper:
634	• Discovery set: It consists of a multi-disease and lifespan population that includes
635	participants from all 12 studies ($N=32,440$). Note that this population does not contain
636	the entire UKBB population but only our first download (July 2017, N=21,305).
637	• Replication set: We held 18,259 participants from the UKBB dataset to replicate the
638	GWAS results. We took these data from our second download of the UKBB dataset
639	(November 2021, <i>N</i> =18,259).
640	• Training population: We randomly drew 250 patients (PT), including AD, MCI, SCZ,
641	ASD, MDD, HTN (hypertension), DM (diabetes mellitus), and 250 healthy controls
642	(CN) per decade from the discovery set, ensuring that the PT and CN groups have
643	similar sex, study and age distributions. The resulting set of 4000 imaging data was used

644 to generate the MuSIC atlas with the sopNMF algorithm. The rationale is to maximize 645 variability across a balanced sample of multiple diseases or risk conditions, age, and 646 study protocols rather than overfit the entire data by including all images in training. 647 Comparison population: To validate sopNMF compared to the original opNMF • 648 algorithm, we randomly subsampled 800 participants from the training population (100 649 per decade for balanced CN and PT). For this scale of sample size, opNMF can load all images into memory for batch learning.⁶⁷ 650 651 All individual studies were approved by their local corresponding Institutional Review 652 Boards (IRB). The iSTAGING and PHENOM consortia consolidated all individual imaging and 653 clinical data; imputed genotype data were directly downloaded from the UKBB website. Data 654 from the UKBB for this project pertains to application 35148. For iSTAGING, the IRB at the 655 University of Pennsylvania (protocol number: 825722) reviewed the research proposal on 656 August 31st, 2016, and updated it on August 31st, 2022. No human subjects were recruited or 657 scanned. Existing de-identified data will be used in this mega-analysis study pooling data from 658 17 studies: BLSA, ADNI1, ADNI2, ADNI3, ACCORD-MIND, LookAhead, SPRINT, 659 CARDIA, MESA, SHIP, BIOCARD, WRAP, Penn-ADC, WHIMS-MRI, AIBL, OASIS, 660 UKBB, MESA, HANDLS. For PHENOM, the IRB at the University of Pennsylvania (protocol number: 828077) reviewed the research proposal on August 19th, 2017. No human subjects were 661 662 recruited or scanned. Existing de-identified data will be used in this meta-analysis study pooling 663 data from 10 studies at Penn, Ludwick-Maximmilian University of Munich, Kings College-664 London, University of Utrecht, University of Melbourne, University of Cantabria, University of 665 Sao Paolo, Xijing Hospital Shaanxi, Tianjin Anning Hospital, and Institute of Mental Health 666 Peking University.

001

668 Method 3: Image processing and statistical harmonization

669 (A): Image processing. Images that passed the quality check (Supplementary eMethod 4) were

670 first corrected for magnetic field intensity inhomogeneity.⁶⁸ Voxel-wise regional volumetric

 $maps (RAVENS)^{35}$ for each tissue volume were then generated by using a registration method to

672 spatially align the skull-stripped images to a template in MNI-space.⁶⁹ We applied sopNMF to

- 673 the RAVENS maps to derive MuSIC.
- 674

675 (B): Statistical harmonization of MuSIC PSCs: We applied MuSIC to the entire population 676 (N=50,699) to extract the multi-scale PSCs. Specifically, MuSIC was applied to each individual's 677 RAVENS gray matter map to extract the sum of brain volume in each PSC. Subsequently, the 678 PSCs were statistically harmonized by an extensively validated approach, i.e., ComBat-GAM¹² 679 (Supplementary eMethod 3) to account for site-related differences in the imaging data. After 680 harmonization, the PSCs were normally distributed (skewness = 0.11 ± 0.17 , and kurtosis = 681 (0.67 ± 0.68) (Supplementary eFigure 7A and B). To alleviate the potential violation of normal 682 distribution in downstream statistical learning, we quantile-transformed all PSCs. In agreement 683 with the literature,^{70,71} males were found to have larger brain volumes than females on average 684 (Supplementary eFigure 7C). Overall, the Combat-GAM model slightly improved data 685 normality across sites (Supplementary eFigure 7E-H). The AAL ROIs underwent the same 686 statistical harmonization procedure.

687

688 Method 4: Genetic analyses

689 Genetic analyses were restricted to the discovery and replication set from UKBB (Method 2). 690 We processed the array genotyping and imputed genetic data (SNPs). The two data sets went through a "best-practice" imaging-genetics quality check (QC) protocol (Method 4A) and were 691 692 restricted to participants of European ancestry. This resulted in 18,052 participants and 8,430,655 693 SNPs for the discovery set and 15,243 participants and 8,470,709 SNPs for the replication set. 694 We reperformed the genetic QC and genetic analyses for the combined populations for 695 BRIDGEPORT, resulting in 33,541 participants and 8,469,833 SNPs. Method 4G details the 696 correction for multiple comparisons throughout our analyses.

697

(A): Genetic data quality check protocol. First, we excluded related individuals (up to 2nd-698 699 degree) from the complete UKBB sample (N=488,377) using the KING software for family 700 relationship inference.⁷² We then removed duplicated variants from all 22 autosomal 701 chromosomes. We also excluded individuals for whom either imaging or genetic data were not 702 available. Individuals whose genetically identified sex did not match their self-acknowledged sex 703 were removed. Other excluding criteria were: i) individuals with more than 3% of missing 704 genotypes; ii) variants with minor allele frequency (MAF) of less than 1%; iii) variants with larger than 3% missing genotyping rate; iv) variants that failed the Hardy-Weinberg test at 1×10^{-10} . To 705 706 adjust for population stratification,⁷³ we derived the first 40 genetic principle components (PC) using the FlashPCA software⁷⁴. The genetic pipeline was also described elsewhere⁷⁵. 707

708

709 (B): Heritability estimates and genome-wide association analysis. We estimated the SNP-

710 based heritability explained by all autosomal genetic variants using GCTA-GREML.⁷⁶ We

711 adjusted for confounders of age (at imaging), age-squared, sex, age-sex interaction, age-squared-

712	sex interaction, ICV, and the first 40 genetic principal components (PC), guided by a previous
713	neuroimaging GWAS ⁴ . In addition, Elliot et al. ⁵ investigated more than 200 confounders in
714	another study. Therefore, our sensitivity analyses included four additional imaging-related
715	covariates (i.e., brain positions and head motion). One-side likelihood ratio tests were performed
716	to derive the heritability estimates. In GWAS, we performed a linear regression for each PSC
717	and included the same covariates as in the heritability estimates using PLINK.77
718	
719	(C): Identification of novel genomic loci. Using PLINK, we clumped the GWAS summary
720	statistics based on their linkage disequilibrium to identify the genomic loci (see Supplementary
721	eMethod 5 for the definition of the index, candidate, independent significant, lead SNP, and
722	genomic locus). In particular, the threshold for significance was set to 5×10^{-8} (<i>clump-p1</i>) for the
723	index SNPs and 0.05 (<i>clump-p2</i>) for the candidate SNPs . The threshold for linkage
724	disequilibrium-based clumping was set to 0.60 (clump-r2) for independent significant SNPs
725	and 0.10 for lead SNPs. The linkage disequilibrium physical-distance threshold was 250
726	kilobases (clump-kb). Genomic loci consider linkage disequilibrium (within 250 kilobases) when
727	interpreting the association results. The GWASRAPIDD ⁷⁸ package (version: 0.99.14) was then
728	used to query the genomic loci for any previously-reported associations with clinical phenotypes
729	documented in the NHGRI-EBI GWAS Catalog ¹⁵ (p-value $< 1.0 \times 10^{-5}$, default inclusion value of
730	GWAS Catalog). We defined a genomic locus as novel when it was not present in GWAS
731	Catalog (query date: April 5 th , 2023).
732	

(D): Gene-level associations with MAGMA. We performed gene-level association analysis
 using MAGMA.¹⁷ First, gene annotation was performed to map the SNPs (reference variant

location from Phase 3 of 1,000 Genomes for European ancestry) to genes (human genome Build
37) according to their physical positions. The second step was to perform the gene analysis based
on the GWAS summary statistics to obtain gene-level p-values between the pairwise 2003 PSCs
and the 18,097 protein-encoding genes containing valid SNPs.

739

(E): Hypothesis-free gene set enrichment analysis with MAGMA. Using the gene-level
association p-values, we performed gene set enrichment analysis using MAGMA. Gene sets
were obtained from Molecular Signatures Database (MsigDB, v7.5.1),⁷⁹ including 6366 curated
gene sets and 10,402 Gene Ontology (GO) terms. All other parameters were set by default for
MAGMA. This hypothesis-free analysis resulted in a more stringent correction for multiple
comparisons (i.e., by the total number of tested genes and PSCs) than the FUMA-prioritized
gene set enrichment analysis (see below F).

747

748 (F): FUMA analyses for the illustrations of specific PSCs. In SNP2GENE, three different 749 methods were used to map the SNPs to genes. First, positional mapping maps SNPs to genes if 750 the SNPs are physically located inside a gene (a 10 kb window by default). Second, expression 751 quantitative trait loci (eQTL) mapping maps SNPs to genes showing a significant eQTL 752 association. Lastly, chromatin interaction mapping maps SNPs to genes when there is a 753 significant chromatin interaction between the disease-associated regions and nearby or distant 754 genes.²⁶ In addition, *GENE2FUNC* studies the expression of prioritized genes and tests for the 755 enrichment of the set of genes in pre-defined pathways. We used the mapped genes as prioritized 756 genes. The background genes were specified as all genes in FUMA, and all other parameters 757 were set by default. We only reported gene sets with adjusted p-value < 0.05.
758

779

759	(G): Correction for multiple comparisons. We practiced a conservative procedure to control
760	for the multiple comparisons. In the case of GWAS, we chose the default genome-wide
761	significant threshold ($5.0x10^{-8}$, and 0.05 for all other analyses) and independently adjusted for
762	multiple comparisons (Bonferroni methods) at each scale by the number of PSCs. We corrected
763	the p-values for the number of phenotypes ($N=6$) for genetic correlation analyses. We adjusted
764	the p-values for the number of PSCs at each scale for heritability estimates. For gene analyses,
765	we controlled for both the number of PSCs at each scale and the number of genes. We adopted
766	these strategies per analysis to correct the multiple comparisons because PSCs of different scales
767	are likely hierarchical and correlated – avoiding the potential of "overcorrection".
768	
769	(H): Replication analysis for genome-wide association studies. We performed GWAS by
770	fitting the same linear regressing models as the discovery set. Also, following the same
771	procedure for consistency, we corrected the multiple comparisons using the Bonferroni method.
772	We corrected it for the number of genomic loci ($N=915$) found in the discovery set with a
773	nominal p-value of 0.05, which thereby resulted in a stringent test with an equivalent p-value
774	threshold of 3.1×10^{-5} (i.e., $(-\log_{10}[p-value] = 4.27)$). We performed a replication for the 915
775	genomic loci, but, in reality, SNPs in linkage disequilibrium with the genomic loci are likely
776	highly significant.
777	

778 Method 5: Pattern analysis via machine learning for individualized imaging signatures

780 have shown its diagnostic and prognostic values.³⁴ Here, we extended the concept of the SPARE

SPARE-AD captures the degree of expression of an imaging signature of AD, and prior studies

- 781 imaging signature to multiple diseases (SPARE-X, X represents disease diagnoses). Following
- our reproducible open-source framework³⁷, we performed nested cross-validation
- 783 (Supplementary eMethod 6) for the machine learning models and derived imaging signatures to
- 784 quantify individualized disease vulnerability.
- 785 SPARE indices. MuSIC PSCs were fit into a linear support vector machine (SVM) to derive
- 786 SPARE-AD, MCI, SCZ, DM, HTN, MDD, and ASD. Specifically, the SVM aims to classify the
- patient group (e.g., AD) from the control group and outputs a continuous variable (i.e., the
- 788 SPARE indices), which indicates the proximity of each participant to the hyperplane in either the
- 789 patient or control space. We compared the classification performance using different sets of
- features: i) the single-scale PSC from 32 to 1024, ii) the multi-scale PSCs by combining all
- features (with and without feature selections embedded in the CV); iii) the ROIs from the AAL
- atlas; and iv) voxel-wise RAVENS maps. The samples selected for each task are presented in

793 Supplementary eTable 2.

No statistical methods were used to predetermine the sample size. The experiments were
not randomized, and the investigators were not blinded to allocation during experiments and
outcome assessment.

797 Data Availability

- 798 The GWAS summary statistics corresponding to this study are publicly available on the
- 799 BRIDGEPORT web portal (<u>https://www.cbica.upenn.edu/bridgeport/</u>) and the MEDICINE web
- 800 portal (<u>http://labs.loni.usc.edu/medicine/</u>). The GWAS summary statistics used in the genetic
- 801 correlation analyses were fetched from the GWAS Catalog platform
- 802 (https://www.ebi.ac.uk/gwas), although each study provided the original links; The GWAS
- 803 Catalog platform was used to query if the SNPs identified by MuSIC were previously reported.

804 Code Availability

- 805 The software and resources used in this study are all publicly available:
- sopNMF: <u>https://pypi.org/project/sopnmf/</u>, MuSIC, and sopNMF (developed for this
- 807 study)
- BRIDGEPORT: <u>https://www.cbica.upenn.edu/bridgeport/</u>, (developed for this study)
- MLNI: <u>https://pypi.org/project/mlni/</u>, machine learning (developed for this study)
- MUSE: <u>https://www.med.upenn.edu/sbia/muse.html</u>, image preprocessing
- PLINK: <u>https://www.cog-genomics.org/plink/</u>, GWAS
- GCTA: <u>https://yanglab.westlake.edu.cn/software/gcta/#Overview</u>, heritability estimates
- LDSC: <u>https://github.com/bulik/ldsc</u>, genetic correlation estimates
- MAGMA: <u>https://ctg.cncr.nl/software/magma</u>, gene analysis
- GWASRAPIDD: <u>https://rmagno.eu/gwasrapidd/articles/gwasrapidd.html</u>, GWAS
- 816 Catalog query
- MsigDB: <u>https://www.gsea-msigdb.org/gsea/msigdb/</u>, gene sets database

819 **Competing Interests**

820 DAW served as Site PI for studies by Biogen, Merck, and Eli Lilly/Avid. He has received 821 consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by 822 Functional Neuromodulation. AJS receives support from multiple NIH grants (P30 AG010133, 823 P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 824 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received 825 support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in-kind contribution of PET 826 tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory 827 Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature 828 Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging, and Behavior). OC 829 reports having received consulting fees from AskBio (2020) and Therapanacea (2022), having 830 received payments for writing a lay audience short paper from Expression Santé (2019), and that 831 his laboratory has received grants (paid to the institution) from Qynapse (2017-present). 832 Members of his laboratory have co-supervised a Ph.D. thesis with myBrainTechnologies (2016-833 2019) and with Qynapse (2017-present). OC's spouse is an employee and holds stock options of 834 myBrainTechnologies (2015-present). OC has a patent registered at the International Bureau of 835 the World Intellectual Property Organization (PCT/IB2016/0526993, Schiratti J-B, Allassonniere 836 S, Colliot O, Durrleman S, A method for determining the temporal progression of a biological 837 phenomenon and associated methods and devices) (2017). ME receives support from multiple 838 NIH grants, the Alzheimer's Association, and the Alzheimer's Therapeutic Research Institute. 839 MZ serves as a consultant and/or speaker for the following pharmaceutical companies: 840 Eurofarma, Lundbeck, Abbott, Greencare, Myralis, and Elleven Healthcare.

842 Authors' contributions

- 843 Dr. Wen takes full responsibility for the integrity of the data and the accuracy of the data analysis.
- 844 Study concept and design: Wen, Davatzikos
- 845 Acquisition, analysis, or interpretation of data: Wen, Nasrallah, Davatzikos, Abdulkadi,
- 846 Satterthwaite, Dazzan, Kahn, Schnack, Zanetti, Meisenzahl, Busatto, Crespo-Facorro, Pantelis,
- 847 Wood, Zhuo, Koutsouleris, Wittfeld, Grabe, Marcus, LaMontagne, Heckbert, Austin, Launer,
- 848 Espeland, Masters, Maruff, Fripp, Johnson, Morris, Albert, Resnick, Saykin, Thompson, Li,
- 849 Wolf, Raquel Gur, Ruben Gur, Shinohara, Tosun-Turgut, Fan, Shou, Erus, Wolk
- 850 Drafting of the manuscript: Wen, Nasrallah, Davatzikos
- 851 Critical revision of the manuscript for important intellectual content: all authors
- 852 Statistical and genetic analysis: Wen

853 **References**

- Alexander-Bloch, A., Giedd, J. N. & Bullmore, E. Imaging structural co-variance between
 human brain regions. *Nat Rev Neurosci* 14, 322–336 (2013).
- 2. Sotiras, A. et al. Patterns of coordinated cortical remodeling during adolescence and their
- associations with functional specialization and evolutionary expansion. *Proc Natl Acad Sci*
- 858 USA **114**, 3527–3532 (2017).
- Blank, S. C., Scott, S. K., Murphy, K., Warburton, E. & Wise, R. J. S. Speech production:
 Wernicke, Broca and beyond. *Brain* 125, 1829–1838 (2002).
- 4. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants
- 862 influencing regional brain volumes and refines their genetic co-architecture with cognitive
- and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).
- 864 5. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK
 865 Biobank. *Nature* 562, 210–216 (2018).
- 866 6. Vignando, M. *et al.* Mapping brain structural differences and neuroreceptor correlates in
 867 Parkinson's disease visual hallucinations. *Nat Commun* 13, 519 (2022).
- 868 7. Bassett, D. S. & Siebenhühner, F. Multiscale Network Organization in the Human Brain. in
- 869 *Multiscale Analysis and Nonlinear Dynamics* 179–204 (John Wiley & Sons, Ltd, 2013).
- doi:10.1002/9783527671632.ch07.
- 871 8. Schaefer, A. et al. Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic
- Functional Connectivity MRI. *Cerebral Cortex* 28, 3095–3114 (2018).
- 873 9. Sotiras, A., Resnick, S. M. & Davatzikos, C. Finding imaging patterns of structural
- 874 covariance via Non-Negative Matrix Factorization. *NeuroImage* **108**, 1–16 (2015).

875	10.	Thomas	Yeo.	B. T.	et al.	The	organization	of the	human	cerebral	cortex	estimated	bv
0,0	- • •		 ,		<i></i>		or genneet on	· · · · · ·			•••••	•	~ ,

- 876 intrinsic functional connectivity. *Journal of Neurophysiology* **106**, 1125–1165 (2011).
- 11. Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D.
- 878 Neurodegenerative diseases target large-scale human brain networks. *Neuron* **62**, 42–52
- 879 (2009).
- Pomponio, R. *et al.* Harmonization of large MRI datasets for the analysis of brain imaging
 patterns throughout the lifespan. *Neuroimage* 208, 116450 (2020).
- 13. Betzel, R. F. & Bassett, D. S. Multi-scale brain networks. *NeuroImage* 160, 73–83 (2017).
- 14. Roshchupkin, G. V. et al. Heritability of the shape of subcortical brain structures in the
- general population. *Nat Commun* **7**, 13738 (2016).
- 885 15. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* 47, D1005–D1012
- 887 (2019).
- 888 16. Wen, J. et al. Genetic, clinical underpinnings of subtle early brain change along
- Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 890 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 17. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
- 892 Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 18. Jossin, Y. Reelin Functions, Mechanisms of Action and Signaling Pathways During Brain
 Development and Maturation. *Biomolecules* 10, E964 (2020).
- 895 19. Gilbert, S. F. Morphogenesis and Cell Adhesion. *Developmental Biology. 6th edition*896 (2000).

- 897 20. Wu, Y. et al. Contacts between the endoplasmic reticulum and other membranes in
- 898 neurons. *Proc Natl Acad Sci U S A* **114**, E4859–E4867 (2017).
- 899 21. Ly, A. et al. DSCAM Is a Netrin Receptor that Collaborates with DCC in Mediating
- 900 Turning Responses to Netrin-1. *Cell* **133**, 1241–1254 (2008).
- 901 22. Nikolsky, Y. et al. Genome-wide functional synergy between amplified and mutated genes
- 902 in human breast cancer. *Cancer Res* **68**, 9532–9540 (2008).
- Bos, P. D. *et al.* Genes that mediate breast cancer metastasis to the brain. *Nature* 459, 1005–1009 (2009).
- 905 24. Lanni, C., Masi, M., Racchi, M. & Govoni, S. Cancer and Alzheimer's disease inverse
- 906 relationship: an age-associated diverging derailment of shared pathways. *Mol Psychiatry*907 **26**, 280–295 (2021).
- 908 25. Shafi, O. Inverse relationship between Alzheimer's disease and cancer, and other factors
- 909 contributing to Alzheimer's disease: a systematic review. *BMC Neurol* **16**, 236 (2016).
- 910 26. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
 911 annotation of genetic associations with FUMA. *Nat Commun* 8, 1826 (2017).
- 912 27. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. *Nature* **407**, 802–809 (2000).
- 913 28. Steiner, E., Tata, M. & Frisén, J. A fresh look at adult neurogenesis. *Nat Med* **25**, 542–543
- 914 (2019).
- 915 29. de Flores, R. *et al.* Medial Temporal Lobe Networks in Alzheimer's Disease: Structural and
 916 Molecular Vulnerabilities. *J Neurosci* 42, 2131–2141 (2022).
- 917 30. Ginestier, C. et al. Prognosis and gene expression profiling of 20q13-amplified breast
- 918 cancers. *Clin Cancer Res* **12**, 4533–4544 (2006).

919	31.	Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new
920		risk loci and implicates A β , tau, immunity and lipid processing. <i>Nat Genet</i> 51 , 414–430
921		(2019).

- 922 32. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
- 923 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 33. Davatzikos, C. Machine learning in neuroimaging: Progress and challenges. *NeuroImage*197, 652–656 (2019).
- 926 34. Davatzikos, C., Xu, F., An, Y., Fan, Y. & Resnick, S. M. Longitudinal progression of
- 927 Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. *Brain*
- 928 **132**, 2026–2035 (2009).
- 929 35. Davatzikos, C., Genc, A., Xu, D. & Resnick, S. M. Voxel-based morphometry using the
- 930 RAVENS maps: methods and validation using simulated longitudinal atrophy. *Neuroimage*931 14, 1361–1369 (2001).
- 932 36. Wen, J. et al. Convolutional neural networks for classification of Alzheimer's disease:

933 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).

934 37. Samper-González, J. et al. Reproducible evaluation of classification methods in

Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* 183,
504–521 (2018).

38. Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F. & Baker, C. I. Circular analysis in
systems neuroscience: the dangers of double dipping. *Nat. Neurosci.* 12, 535–540 (2009).

- 939 39. Doshi, J. *et al.* MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration
- 940 algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195

941 (2016).

- 942 40. Diamantopoulou, Z. *et al.* The metastatic spread of breast cancer accelerates during sleep.
 943 *Nature* 607, 156–162 (2022).
- 944 41. Barton, R. A. & Venditti, C. Rapid Evolution of the Cerebellum in Humans and Other
- 945 Great Apes. *Curr Biol* **27**, 1249–1250 (2017).
- 946 42. van der Meer, D. *et al.* Understanding the genetic determinants of the brain with MOSTest.
- 947 *Nat Commun* **11**, 3512 (2020).
- 43. Soheili-Nezhad, S., Beckmann, C. F. & Sprooten, E. Reproducibility of Principal and
- 949 Independent Genomic Components of Brain Structure and Function. 2022.07.13.499912
- 950 Preprint at https://doi.org/10.1101/2022.07.13.499912 (2022).
- 951 44. Patel, K. et al. New phenotype discovery method by unsupervised deep representation
- learning empowers genetic association studies of brain imaging. 2022.12.10.22283302
- 953 Preprint at https://doi.org/10.1101/2022.12.10.22283302 (2022).
- 45. Yang, Z. et al. Gene-SGAN: a method for discovering disease subtypes with imaging and
- 955 genetic signatures via multi-view weakly-supervised deep clustering. ArXiv
- 956 arXiv:2301.10772v1 (2023).
- 46. Eickhoff, S. B., Yeo, B. T. T. & Genon, S. Imaging-based parcellations of the human brain. *Nat Rev Neurosci* 19, 672–686 (2018).
- 47. Chen, C.-H. *et al.* Hierarchical Genetic Organization of Human Cortical Surface Area. *Science* 335, 1634–1636 (2012).
- 48. Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex. *Nature* 536, 171–
 178 (2016).
- 963 49. Sunkin, S. M. *et al.* Allen Brain Atlas: an integrated spatio-temporal portal for exploring the
 964 central nervous system. *Nucleic Acids Res* 41, D996–D1008 (2013).

- 965 50. Munafò, M. R. et al. A manifesto for reproducible science. Nat Hum Behav 1, 1–9 (2017).
- 966 51. Poldrack, R. A. et al. Scanning the horizon: towards transparent and reproducible
- 967 neuroimaging research. Nat. Rev. Neurosci. 18, 115–126 (2017).
- 968 52. Routier, A. et al. Clinica: An Open-Source Software Platform for Reproducible Clinical
- 969 Neuroscience Studies. Frontiers in Neuroinformatics 15, 39 (2021).
- 970 53. Wen, J. et al. Reproducible Evaluation of Diffusion MRI Features for Automatic
- 971 Classification of Patients with Alzheimer's Disease. *Neuroinformatics* **19**, 57–78 (2021).
- 972 54. Zhirong Yang & Oja, E. Linear and Nonlinear Projective Nonnegative Matrix
- 973 Factorization. IEEE Trans. Neural Netw. 21, 734–749 (2010).
- 974 55. Petersen, R. C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical 975 characterization. Neurology 74, 201–209 (2010).
- 976 56. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective 977
- epidemiological study. Nat Neurosci 19, 1523–1536 (2016).
- 978 57. Ellis, K. A. *et al.* The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging:
- 979 methodology and baseline characteristics of 1112 individuals recruited for a longitudinal
- 980 study of Alzheimer's disease. Int. Psychogeriatr. 21, 672–687 (2009).
- 981 58. Soldan, A. et al. Relationship of medial temporal lobe atrophy, APOE genotype, and
- 982 cognitive reserve in preclinical Alzheimer's disease. Hum Brain Mapp 36, 2826–2841 983 (2015).
- 984 59. Resnick, S. M., Pham, D. L., Kraut, M. A., Zonderman, A. B. & Davatzikos, C.
- 985 Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J
- 986 Neurosci 23, 3295–3301 (2003).

- 87 60. Resnick, S. M. *et al.* One-year age changes in MRI brain volumes in older adults. *Cereb*88 *Cortex* 10, 464–472 (2000).
- 989 61. Friedman, G. D. *et al.* CARDIA: study design, recruitment, and some characteristics of the
- 990 examined subjects. *J Clin Epidemiol* **41**, 1105–1116 (1988).
- 991 62. LaMontagne, P. J. et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive
- Dataset for Normal Aging and Alzheimer Disease. 2019.12.13.19014902 Preprint at
- 993 https://doi.org/10.1101/2019.12.13.19014902 (2019).
- 63. Resnick, S. M. et al. Postmenopausal hormone therapy and regional brain volumes: the
- 995 WHIMS-MRI Study. *Neurology* **72**, 135–142 (2009).
- 996 64. Johnson, S. C. et al. The Wisconsin Registry for Alzheimer's Prevention: A review of
- 997 findings and current directions. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease*998 *Monitoring* 10, 130–142 (2018).
- 65. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using
 machine learning. *Brain* 143, 1027–1038 (2020).
- 1001 66. Di Martino, A. *et al.* Enhancing studies of the connectome in autism using the autism brain
 1002 imaging data exchange II. *Sci Data* 4, 170010 (2017).
- 1003 67. Shalev-Shwartz, S., Singer, Y. & Ng, A. Y. Online and batch learning of pseudo-metrics. in
- 1004 *Proceedings of the twenty-first international conference on Machine learning* 94
- 1005 (Association for Computing Machinery, 2004). doi:10.1145/1015330.1015376.
- 1006 68. Tustison, N. J. *et al.* N4ITK: improved N3 bias correction. *IEEE Trans. Med. Imaging* 29, 1310–1320 (2010).
- 1008 69. Ou, Y., Sotiras, A., Paragios, N. & Davatzikos, C. DRAMMS: Deformable Registration via
- 1009 Attribute Matching and Mutual-Saliency Weighting. *Med Image Anal* **15**, 622–639 (2011).

- 1010 70. Coupé, P., Catheline, G., Lanuza, E., Manjón, J. V. & Initiative, for the A. D. N. Towards a
- 1011 unified analysis of brain maturation and aging across the entire lifespan: A MRI analysis.
- 1012 *Human Brain Mapping* **38**, 5501–5518 (2017).
- 1013 71. Bethlehem, R. a. I. et al. Brain charts for the human lifespan. 2021.06.08.447489
- 1014 https://www.biorxiv.org/content/10.1101/2021.06.08.447489v1 (2021)
- 1015 doi:10.1101/2021.06.08.447489.
- 1016 72. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
 1017 *Bioinformatics* 26, 2867–2873 (2010).
- 1018 73. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
- 1019 stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1020 74. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank1021 scale genotype datasets. *Bioinformatics* 33, 2776–2778 (2017).
- 1022 75. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- 1023 Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry
- 1024 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 1025 76. Yang, J., Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. GCTA-GREML
- 1026 accounts for linkage disequilibrium when estimating genetic variance from genome-wide
- 1027 SNPs. *PNAS* **113**, E4579–E4580 (2016).
- 1028 77. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
 1029 Linkage Analyses. *Am J Hum Genet* 81, 559–575 (2007).
- 1030 78. Magno, R. & Maia, A.-T. gwasrapidd: an R package to query, download and wrangle
- 1031 GWAS catalog data. *Bioinformatics* **36**, 649–650 (2020).

- 1032 79. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for
- 1033 interpreting genome-wide expression profiles. *Proceedings of the National Academy of*
- 1034 *Sciences* **102**, 15545–15550 (2005).
- 1035 80. Kuhn, H. W. The Hungarian method for the assignment problem. *Naval Research Logistics*
- 1036 *Quarterly* **2**, 83–97 (1955).
- 1037 81. Stasinopoulos, D. M. & Rigby, R. A. Generalized Additive Models for Location Scale and
- 1038 Shape (GAMLSS) in R. Journal of Statistical Software 23, 1–46 (2008).
- 1039 82. Klein, A. & Tourville, J. 101 Labeled Brain Images and a Consistent Human Cortical
- 1040 Labeling Protocol. *Frontiers in Neuroscience* **6**, 171 (2012).
- 1041 83. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. in Advances in Neural
- 1042 Information Processing Systems 12 (eds. Solla, S. A., Leen, T. K. & Müller, K.) 307–313
- 1043 (MIT Press, 2000).

1045 Acknowledgments

- 1046 The iSTAGING consortium is a multi-institutional effort funded by NIA by RF1 AG054409.
- 1047 The Baltimore Longitudinal Study of Aging neuroimaging study is funded by the Intramural
- 1048 Research Program, National Institute on Aging, National Institutes of Health and by
- 1049 HHSN271201600059C. The BIOCARD study is in part supported by NIH grant U19-
- 1050 AG033655. The PHENOM study is funded by NIA grant R01MH112070 and by the PRONIA
- 1051 project as funded by the European Union 7th Framework Program grant 602152. Other
- supporting funds are 5U01AG068057, 1U24AG074855, and S10OD023495. Data were provided
- 1053 [in part] by OASIS OASIS-3: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH
- 1054 P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1
- 1055 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a
- 1056 wholly owned subsidiary of Eli Lilly. OC has received funding from the French government
- 1057 under management of Agence Nationale de la Recherche as part of the "Investissements
- 1058 d'avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute) and reference ANR-
- 1059 10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Institut Hospitalo-Universitaire-6). This
- 1060 research has been conducted using the UK Biobank Resource under Application Number 35148.
- 1061 Data used in preparation of this article were in part obtained from the Alzheimer's Disease
- 1062 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
- 1063 the ADNI contributed to the design and implementation of ADNI and/or provided data but did
- 1064 not participate in the analysis or writing of this report. A complete listing of ADNI investigators
- 1065 can be found
- 1066 at: <u>http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</u>.
- 1067 ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging

1068 and Bioengineering, and through generous contributions from the following: AbbVie,

1069 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, 1070 Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan 1071 Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its 1072 affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer 1073 Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research 1074 & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; 1075 NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. 1076 1077 The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in 1078 Canada. Private sector contributions are facilitated by the Foundation for the National Institutes 1079 of Health (www.fnih.org). The grantee organization is the Northern California Institute for 1080 Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research 1081 Institute at the University of Southern California. ADNI data are disseminated by the Laboratory 1082 for Neuro Imaging at the University of Southern California. Dr. Wen and Dr. Davatzikos had full 1083 access to all the data in the study. They took responsibility for the integrity of the data and the 1084 accuracy of the data analysis.

1086 Novel genomic loci influence patterns of structural covariance in the human 1087 brain

1088

Junhao Wen^{1,2*}, Ilya M. Nasrallah^{2,3}, Ahmed Abdulkadir², Theodore D. Satterthwaite^{2,4}, Zhijian Yang²,
Guray Erus², Timothy Robert-Fitzgerald⁵, Ashish Singh², Aristeidis Sotiras⁶, Aleix Boquet-Pujadas⁷,
Elizabeth Mamourian², Jimit Doshi², Yuhan Cui², Dhivya Srinivasan², Ioanna Skampardoni², Jiong

- 1092 Chen², Gyujoon Hwang², Mark Bergman², Jingxuan Bao⁸, Yogasudha Veturi⁹, Zhen Zhou², Shu Yang⁸,
- 1093 Paola Dazzan¹⁰, Rene S. Kahn¹¹, Hugo G. Schnack¹², Marcus V. Zanetti¹³, Eva Meisenzahl¹⁴, Geraldo F.
- 1094 Busatto¹³, Benedicto Crespo-Facorro¹⁵, Christos Pantelis¹⁶, Stephen J. Wood¹⁷, Chuanjun Zhuo¹⁸, Russell
- T. Shinohara^{2,5}, Ruben C. Gur⁴, Raquel E. Gur⁴, Nikolaos Koutsouleris¹⁹, Daniel H. Wolf^{2,4}, Andrew J.
 Saykin²⁰, Marylyn D. Ritchie⁹, Li Shen⁸, Paul M. Thompson²¹, Olivier Colliot²², Katharina Wittfeld²³,
- Hans J. Grabe²³, Duygu Tosun²⁴, Murat Bilgel²⁵, Yang An²⁵, Daniel S. Marcus²⁶, Pamela LaMontagne²⁶
- 1098 Susan R. Heckbert²⁷, Thomas R. Austin²⁷, Lenore J. Launer²⁸, Mark Espeland²⁹, Colin L Masters³⁰, Paul
- 1099 Maruff³⁰, Jurgen Fripp³¹, Sterling C. Johnson³², John C. Morris³³, Marilyn S. Albert³⁴, R. Nick Bryan³,
- 1100 Susan M. Resnick²⁵, Yong Fan², Mohamad Habes³⁵, David Wolk^{2,36}, Haochang Shou^{2,5}, and Christos
- 1101 Davatzikos^{2*}, for the iSTAGING, the BLSA, the BIOCARD, the PHENOM, the ADNI studies, and the
- 1102 AI4AD consortium
- 1103
- ¹Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School of
 Medicine of USC, University of Southern California, Los Angeles, California, USA.
- ²Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for Biomedical Image Computing and
- 1107 Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- ³Department of Radiology, University of Pennsylvania, Philadelphia, USA.
- 1109 ⁴Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- ⁵Penn Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology, and Informatics,
- 1111 Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 1112 ⁶Department of Radiology and Institute for Informatics, Washington University School of Medicine, St. Louis, USA
- ⁷Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- ⁸Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine,
 Philadelphia, USA
- ⁹Department of Genetics and Institute for Biomedical Informatics, Perelman School of Medicine, University of
 Pennsylvania, Philadelphia, PA, USA
- 1118 ¹⁰Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College
- 1119 London, London, UK
- 1120 ¹¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
- 1121 ¹²Department of Psychiatry, University Medical Center Utrecht, Utrecht, Netherlands
- ¹³Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
- 1123 ¹⁴ Department of Psychiatry and Psychotherapy, HHU Düsseldorf, Germany
- 1124 ¹⁵Hospital Universitario Virgen del Rocio, University of Sevilla-IBIS; IDIVAL-CIBERSAM, Sevilla, Spain
- ¹⁶Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health,
- 1126 Carlton South, Australia
- 1127 ¹⁷Orygen and the Centre for Youth Mental Health, University of Melbourne; and the School of Psychology,
- 1128 University of Birmingham, UK
- ¹⁸key Laboratory of Real Tine Tracing of Brain Circuits in Psychiatry and Neurology (RTBCPN-Lab), Nankai
- University Affiliated Tianjin Fourth Center Hospital; Department of Psychiatry, Tianjin Medical University, Tianjin,
 China
- ¹⁹Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University, Munich, Germany
- ²⁰Radiology and Imaging Sciences, Center for Neuroimaging, Department of Radiology and Imaging Sciences,
- 1134 Indiana Alzheimer's Disease Research Center and the Melvin and Bren Simon Cancer Center, Indiana University
- 1135 School of Medicine, Indianapolis
- 1136 ²¹Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of
- 1137 Medicine of USC, University of Southern California, Marina del Rey, California

- 1138 ²²Sorbonne Université, Institut du Cerveau Paris Brain Institute ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la
- 1139 Pitié Salpêtrière, F-75013, Paris, France
- ¹¹⁴⁰²³Department of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), University
- 1141 Medicine Greifswald, Germany
- 1142 ²⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
- 1143 ²⁵Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, USA
- ²⁶Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
- ²⁷Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA,
 USA
- ²⁸Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA
- 1148 ²⁹Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, 1149 North Carolina, USA
- ³⁰Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- ³¹CSIRO Health and Biosecurity, Australian e-Health Research Centre CSIRO, Brisbane, Queensland, Australia
- ³²Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
- ³³Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
- ³⁴Department of Neurology, Johns Hopkins University School of Medicine, USA
- ³⁵Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at
- 1157 San Antonio, San Antonio, USA
- ³⁶Department of Neurology and Penn Memory Center, University of Pennsylvania, Philadelphia, USA
- 1159
- 1160 *Corresponding authors:
- 1161 Junhao Wen, Ph.D. junhaowe@usc.edu
- 1162 <u>2025 Zonal Ave, Los Angeles, CA 90033, United States</u>
- 1163 Christos Davatzikos, Ph.D. <u>Christos.Davatzikos@pennmedicine.upenn.edu</u>
- 1164 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States

- 1166 eMethod 1: Empirical validation of sopNMF
- 1167 eMethod 2: Reproducibility index
- 1168 eMethod 3: Inter-site image harmonization
- 1169 eMethod 4: Quality check of the image processing pipeline
- 1170 eMethod 5 Definition of the index, candidate, independent significant, and SNP and
- 1171 genomic locus
- 1172 eMethod 6 Cross-validation procedure for PAML
- 1173 eFigure 1: Comparison between opNMF and sopNMF
- 1174 eFigure 2: Reproducibility of the sopNMF brain parcellation
- 1175 eFigure 3: Scatter plot for the h^2 estimates from the discovery and replication sets
- 1176 eFigure 4: Sensitivity check for the GWAS results using the discovery set in UKBB
- 1177 eFigure 5: Machine learning performance for disease classification and age prediction
- 1178 eFigure 6: Annotation of MUSE PSCs to MuSIC PSCs based on the overlap index
- 1179 eFigure 7: Summary statistics of the multi-scale PSCs of MuSIC
- 1180 eTable 1: Study cohort characteristics
- 1181 eTable 2: Clinical phenotypes and diagnoses used in machine learning classification
- 1182 eTable 3: Comparison of variants identified via MuSIC with other studies
- 1183 eTable 4: Classification balanced accuracy for disease classification and effect size of these
- 1184 imaging signatures
- 1185 eTable 5: 119 MUSE gray matter regions of interest
- 1186 eAlgorithm 1: Algorithm for sopNMF
- 1187

1188 eMethod 1: Empirical validation of sopNMF.

1189	For the empirical validation of sopNMF, the comparison population (Method 1 in the main
1190	manuscript) was used so that the machine's memory could be sufficient to read the entire data for
1191	opNMF. For sopNMF, different choices of batch size (i.e., BS=32, 64, 128, and 256) were
1192	tested. We hypothesized that sopNMF could approximate the optima of opNMF during
1193	optimization, i.e., resulting in similar parts-based representation, training loss, and sparsity.
1194	TensorboardX was embedded into the sopNMF framework to monitor the training process
1195	dynamically. All experiments were performed on an Ubuntu machine with a maximum RAM of
1196	32 GB and 8 CPUs. The predefined maximum number of epochs for all experiments is 50,000,
1197	and the tolerance of early stopping criteria is 100 epochs based on the training loss.
1198	We qualitatively compared the extracted PSCs and quantitatively for the training loss, the
1199	sparsity of the component matrix W , and the memory consumption for $C=20$ (number of PSCs).
1200	The 20 PSCs were spatially consistent between opNMF and sopNMF, despite that some regions
1201	were decomposed into different PSCs (i.e., the white ellipse in eFig. 1A). For the training loss,
1202	opNMF obtained the lowest loss (1.103 x 10^6), and the loss of sopNMF were 1.107 x 10^6 , 1.108
1203	$x10^{6}$, 1.111 $x10^{6}$ and 1.210 $x10^{6}$ for BS =256, 128, 64, and 32, respectively (eFig. 1D). For the
1204	sparsity of the component matrix, all models obtained comparable results (sparsity ≈ 0.83 , eFig.
1205	1E). The estimated memory consumptions during the training process were 28.65, 4.02, 3.81,
1206	2.60, 1.47 GB for opNMF and sopNMF (BS =256, 128, 64, and 32), respectively
1207	(Fig. e1F).

1209	eMethod 2: Reproducibility index.
1210	We proposed a reproducibility index (RI) to test the reproducibility of sopNMF for brain
1211	parcellation:
1212	• We used the Hungarian match algorithm ⁸⁰ to match the pairs of PSCs between two splits
1213	under the specific condition that maximizes the similarity (i.e., minimizes the cost of
1214	workers/jobs in its original formulation).
1215	• For each pair of PSCs, we calculated the inner product of the vectors (R^d) , referred to as
1216	RI. This index takes values between [0, 1], with higher values indicating higher
1217	reproducibility.
1218	• For each scale <i>C</i> , we presented the mean/standard deviation of the RIs for all PSCs.
1219	
1220	
1221	

1222 eMethod 3: Inter-site image harmonization

We used an extensively validated statistical harmonization approach, i.e., ComBat-GAM,¹² to harmonize the extracted multi-scale PSCs. This method estimates the variability in volumetric measures due to differences in site/cohort-specific imaging protocols based on variances observed within and across control groups while preserving normal variances due to age, sex, and intracranial volume (ICV) differences. The model was initially trained on the discovery set and then applied to the replication set.

1230 eMethod 4: Quality check of the image processing pipeline.

- 1231 Raw T1-weighted MRIs were first quality checked (QC) for motion, image artifacts, or restricted
- 1232 field-of-view. Another QC was performed: First, the images were examined by manually
- 1233 evaluating for pipeline failures (e.g., poor brain extraction, tissue segmentation, and registration
- 1234 errors). Furthermore, a second step automatically flagged images based on outlying values of
- 1235 quantified metrics (i.e., PSC values); those flagged images were re-evaluated.
- 1236

1237 eMethod 5: Definition of the index, candidate, independent significant, and lead SNP and

- 1238 genomic locus.
- 1239 Index SNP
- 1240 They are defined as SNPs with a p-value threshold \leq 5e-8 (*clump-p1*) from GWAS summary
- 1241 statistics.
- 1242 Independent significant SNP
- 1243 They are defined as the index SNPs, which are independent of each other (not in linkage
- 1244 disequilibrium) with $r^2 \le 0.6$ (*clump-r2*) within 250 kilobases (non-overlapping, *clump-kb*) away
- 1245 from each other.
- 1246 Lead SNP and genomic loci
- 1247 They are defined as the independent significant SNPs, which are independent of each other with
- 1248 a more stringent $r^2 \le 0.1$ (*clump-r2*) within 250 kilobases (non-overlapping, *clump-kb*) away
- 1249 from each other. Each of these clumps is defined as a *genomic locus*.
- 1250 Candidate SNP
- 1251 With each genomic locus, candidate SNPs are defined as the SNPs whose association p-values
- 1252 are smaller than 0.05 (*clump-p2*). The definitions followed instructions from FUMA²⁶ and
- 1253 Plink⁷⁷ software.

1254 eMethod 6: Cross-validation procedure for PAML.

- 1255 Nested cross-validation was adopted for all tasks following the good-practice guidelines
- 1256 proposed in our previous works 36,37,53 . In particular, an outer loop was used to evaluate the task
- 1257 performance (250 repetitions of random hold-out splits with 80% of data for training). In
- 1258 contrast, an inner loop focused on tuning the hyperparameters (10-fold splits). We computed the
- 1259 balanced accuracy (BA) to evaluate the classification tasks. We calculated the effect size
- 1260 (Cohen's *d*) and p-value for each SPARE index to quantify its discriminative power.



1262

eFigure 1: Comparison between opNMF and sopNMF. (A) Qualitative evaluation: The extracted components are shown in the original image space, with each PSC displayed in a distinct color. The white ellipse indicates the region where the models diverge. Quantitative evaluation: training loss (B, D) and sparsity (C, E) demonstrated similar patterns between models, except that batch size (BS) = 32 had a larger loss than the other models. Comparing the estimated memory consumption during training across models shows significant advantages for all sopNMF models compared to opNMF.



1270

eFigure 2: Reproducibility of the sopNMF brain parcellation. In general, sopNMF

- 1272 demonstrated high reproducibility under various conditions. For each brain PSC, the
- 1273 reproducibility index (RI) was calculated (**Supplementary eMethod 2**). (A) Split-sample 1274 analyses, where the training normalitien (N = 4000) was readered with a first two belows while
- analyses, where the training population (N=4000) was randomly split into two halves while
- 1275 maintaining similar age, sex, and site distribution between groups. (**B**) Split-sex analyses, where
- 1276 the training population was divided into males and females. Colored PSCs on the brain template
- 1277 illustrate the same PSC independently derived from the two splits. (C) Leave-one-site-out
- analyses for C32 PSCs., where the training populations excluding participants from each site
- 1279 (BIOCARD, ADNI, WARP, AIBL, ABIDE, BLSA, OASIS, CARDIA, PHENOM, PENN,
- 1280 UKBB, and WHIMS) were independently trained with sopNMF. The RI indices were compared
- to the sopNMF results using the full training sample (N=4000).
- 1282

medRxiv preprint doi: https://doi.org/10.1101/2022.07.20.22277727; this version posted July 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



1284 1285 eFigure 3: Scatter plot for the h^2 estimates from the discovery and replication sets. The 1286 SNP-based heritability was estimated independently for the discovery set (N=18,052) and replication set (N=15,243). In particular, the two estimates were highly correlated (r = 0.94, p-1287 1288 value $< 10^{-6}$), demonstrating a highly similar genetic architecture across different sets of UKBB 1289 data.



1292 eFigure 4: Sensitivity check for the GWAS results using the discovery set in UKBB. A) The

- 1293 GWAS results for participants with European ancestry in the discovery set. **B**) The GWAS
- results for participants with European ancestry in the discovery and replication sets. **C**) The
- 1295 GWAS results for participants with all different ancestries in the discovery set. **D**) The GWAS

- 1296 results for participants with European ancestry in the discovery set by adding four additional
- 1297 imaging-related covariates. E) The GWAS results for participants with non-European ancestry in
- 1298 the discovery set. **F**) The GWAS results for participants with the independent ADNI WGS data.



eFigure 5: Machine learning performance for disease classification. Balanced accuracy (BA)
for each classification task using different features from multi-scale MuSIC, AAL, and RAVENS
(higher score better). Details are presented in eTable 4.

1303



- 1304
- 1305 **eFigure 6: Annotation of MUSE ROIs to MuSIC PSCs based on the overlap index**. We
- automatically annotated the 119 MUSE GM PSCs to the MuSIC atlases at all six scales (C=32,
- 1307 64, 128, 256, 512, and 1024). To this end, we calculated an overlap index (OI) to quantify the
- 1308 spatial overlaps between MUSE and MuSIC. For instance, for each MUSE PSC (eTable 5) vs.
- each of the 32 PSCs of MuSIC at C=32 scale, the OI equals the proportion of the number of
- 1310 overlap voxels and the total number of voxels in the MUSE PSC. Here we illustrate by mapping
- the right thalamus of MUSE to all 6 MuSIC atlases. The highest OIs are 0.82, 0.70, 0.86, 0.30,
- 1312 0.09, 0.05 for C32_1, C64_42, C128_114, C256_110, C512_249, and C1024_249 PSCs. This
- 1313 functionality is available in BRIDGEPORT:
- 1314 https://www.cbica.upenn.edu/bridgeport/MUSE/Right%20Thalamus%20Proper
- 1315



eFigure 7: Summary statistics of the multi-scale PSCs of MuSIC. Multi-scale PSCs show
 considerable normal distributions, i.e., symmetrical distribution (A) with a low kurtosis (B).

- 1319 Moreover, we fit the Generalized Additive Model for Location, Scale, and Shape (GAMLSS)⁸¹
- 1320 model (fractional polynomials with 2 degrees) to each PSC to delineate the age trajectory over
- 1321 the lifespan in males (solid lines) and females (dotted lines), respectively (**C**). For visualization

- 1322 purposes, we selectively display the first 10 PSCs from each scale of the MuSIC atlases. In
- 1323 general, males have larger brain volumes than females. For **D-F**, we selectively showed the
- 1324 distribution of age (**D**) and the distribution of PSC volume before harmonization (**E**) and after
- harmonization (**F**) for C32_1 within each site in the discovery set. For **G** and **H**, we tested the
- 1326 normality of the PSC volume (C32_1) from each pair of sites using the Shapiro-Wilk test
- 1327 (*scipy.stats.shapiro* function) in the discovery set before (**G**) harmonization and after
- harmonization (**H**). A higher $-\log_{10}(P)$ indicates the data are less likely to be normally
- 1329 distributed. As a general trend, our statistical harmonization techniques demonstrated a slight
- 1330 improvement in the normality of the data. Additionally, we consistently applied normality
- transformations to all statistical analyses, including GWAS, to mitigate any non-normality.
- 1332

1333 eTable 1. Study cohort characteristics.

1334The current study consists of two main populations/sets: the discovery set (N=32,440, including1335participants from the first download of the UKBB data) and the replication set (N=18,259, the1336second download of the UKBB data). To train the sopNMF model for MuSIC, we selected 250

patients (PT) and 250 healthy controls (CN) for each decade of the discovery set, resulting in

1338 4000 participants in total, referred to as the training population. Age ranges from 5 to 97 years

- and is shown with mean and standard deviation. Sex is displayed with the number and
- percentage of female participants. Data was collected from 12 studies, 130 sites, and 12
- countries. The number of sites (country) per study is detailed as follows:
- 1342 ADNI: 63 sites (USA)
- UKBB: 5 sites (UK)
- AIBL: 2 sites (Australia)
- BIOCARD: 2 sites (USA)
- BLSA: 1 site (USA)
- CARDIA: 3 sites (USA)
- OASIS: 1 site (USA)
- 1349
 • PENN: 1 site (USA)
- 1350 WHIMS: 14 sites (USA)
- WRAP 1 site (USA)
- PHENOM: 12 sites (China, Brazil, Australia, Germany, Spain, USA, Netherlands)

• ABIDE: 25 sites (USA, Netherlands, Belgium, Germany, Ireland, Switzerland, France)

Abbreviations: CN: healthy control; AD: Alzheimer's disease; MCI: mild cognitive impairment;
SCZ: schizophrenia; ASD: autism spectrum disorder; MDD: major depressive disorder; DM:

1356 diabetes; HTN: hypertension.

^aUKBB data were separately downloaded two times: the first was the N=21,305 in the discovery

1358 set, and the second was the replication set.

¹³⁵⁹ ^bWe define CN (healthy controls) as participants that do not have any of the diseases listed here.

These CN participants might have diagnoses of other illnesses or comorbidities (e.g., participantsfrom UKBB have a wide range of pathology based on ICD-10).

Study	N (50,699)	Age (5-97 year)	Sex (female/%)	CN ^b	AD	MCI	SCZ	ASD	MDD	DM	HTN
Discovery set	32,440	60.04 <u>+</u> 14.87	16,868/52	24,98 0	954	1288	1094	597	1476	1093	958
ADNI	1765	73.66 <u>+</u> 7.19	798/45	297	343	875	NA	NA	NA	NA	250
UKBB ^a	21,305	62.58 <u>+</u> 7.48	10,101/53	18,73 5	1	NA	NA	NA	1476	1093	NA
AIBL	830	71.36 <u>+</u> 6.78	471/57	625	86	115	NA	NA	NA	NA	4
BIOCARD	288	58.15± 10.54	115/60	283	1	4	NA	NA	NA	NA	NA
BLSA	1114	65.44 <u>+</u> 14.11	589/53	729	9	11	NA	NA	NA	NA	365
CARDIA	892	51.21± 3.98	471/53	620	NA	NA	NA	NA	NA	NA	272
OASIS	983	69.92 <u>+</u> 9.75	557/57	759	220	NA	NA	NA	NA	NA	4
set ^a	10,237	7.43	7172/33	1 171	1111	INA	1171	11/1	11/1	1171	117
------------------	--------	-------------	---------	-------	------	------	------	------	------	------	-----
Replication	18 259	$54.70\pm$	9742/53	NA	NA	NA	NA	NA	NA	NA	NA
ADIDE	1220	9.01	203/17	025	INA	INA	INA	597	INA	INA	INA
ADIDE	1220	17.92±	202/17	672	NIA	NIA	NI A	507	NIA	NA	ΝA
FIENOM	2123	10.60	034/40	1051	INA	NA	1094	INA	INA	INA	INA
DUENOM	2125	$30.21 \pm$	854/40	1021	NIA	NIA	1004	ΝIΛ	NIA	NA	ΝA
WKAP	110	6.06	19/08	110	INA	INA	INA	INA	INA	INA	INA
	116	63.36±	70/69	116	NT A	NI A	NT A	NT A	NI A	NLA	NIA
W HINIS	995	3.64	993/100	980	INA	INA	INA	INA	INA	INA	0
WHIME	005	69.61±	005/100	096	NIA	NIA	ΝA	ΝIΛ	NIA	NA	6
PEININ	807	10.65	333/39	1/5	294	285	ΝA	INA	INA	INA	57
DENIN	907	72.63±	222/50	172	204	202	NT A	NT A	NT A	NT A	57

1365	eTable 2: Clinical phenotypes and diagnoses used in machine learning classification.						
1366	We harmonized the population of the phenotypes of interest per study definitions:						
1367	• We combined AD and MCI patients from ADNI, PENN, and AIBL but excluded OASIS						
1368	subjects because of the different diagnostic criteria of an AD patient in OASIS.						
1369	• For several binary disease phenotypes, we used the ICD-10 diagnosis						
1370	(https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=41270). Note that ICD-10 diagnoses are						
1371	generally collected from the participants' medical inpatient records. We first included						
1372	diseases from the following categories:						
1373	• Diseases of the blood and blood-forming organs and certain disorders involving the						
1374	immune mechanism (D-XXX, XXX represents the ID of a specific disease);						
1375	• Endocrine, nutritional, and metabolic diseases (E-XXX);						
1376	• Mental and behavioral disorders (F-XXX);						
1377	• Diseases of the nervous system (G-XXX);						
1378	• Diseases of the circulatory system (I-XXX).						
1379	We then set a threshold of 75 patients for any ICD-10 diagnosis. We finally randomly						
1380	selected age and sex-matched healthy controls (excluding all patients in all diagnoses). ^a :						
1381	For major depressive disorder, we used the inclusion criteria from our previous work. ⁷⁵						
1382	• For cognitive scores, we included:						
1383	• Tower rearranging (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=21004</u>)						
1384	• Matrix pattern (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6373</u>)						
1385	 TMT-A (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6348</u>) 						
1386	 TMT-B (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6350</u>) 						
1387	 DSST (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23324</u>) 						
1388	 Pairs matching (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=399</u>) 						
1389	 Numerical memory (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=4282</u>) 						
1390	 Prospective memory (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=4288</u>) 						
1391	 Reaction time (<u>https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20023</u>) 						
1392	 Fluid intelligence (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20016) 						
1393	AD: Alzheimer's disease; MCI: mild cognitive impairment; SCZ: schizophrenia; DM: diabetes						
1394	mellitus; MDD: major depressive disorder; HTN: hypertension; ASD: autism spectrum disorder;						

1396 1397 cognitive scores from different studies.

1395

Trait (ICD-10 code or ID)	Sample size (CN/PT or <i>N</i>)	Site	Trait (ICD-10 code or ID)	Sample size (CN/PT or <i>N</i>)	Site
AD	1095/723	ADNI, PENN, & AIBL	Carpal tunnel syndrome (G560)	901/901	UKBB
MCI	1273/1095	ADNI, PENN, & AIBL	Lesion of ulnar nerve (G562)	104/104	UKBB
SCZ	1031/1094	PHENOM	Lesion of plantar nerve (G576)	163/163	UKBB
DM	1093/1093	UKBB	Angina pectoris (I20)	1535/1535	UKBB
MDD ^a	1476/1476	UKBB	Acute myocardial infarction (I21)	769/769	UKBB
HTN	934/887	ADNI, BLSA & CARDIA	Chronic ischaemic heart disease (I25)	2217/2217	UKBB

CN: healthy control; PT: patient; N: number of participants. We decided not to harmonize

ASD	623/597	ABIDE	Pulmonary embolism (I20)	351/351	UKBB
Iron deficiency anemia (D50)	1012/1012	UKBB	Cardiomyopathy (I42)	116/116	UKBB
Vitamin B12 deficiency anemia (D50)	78/78	UKBB	Paroxysmal tachycardia (I47)	320/320	UKBB
Agranulocytosis (D70)	245/245	UKBB	Heart failure (I50)	436/436	UKBB
Thyrotoxicosis (E05)	205/205	UKBB	Cerebral infarction (I63)	291/291	UKBB
Vitamin D deficiency (E55)	180/180	UKBB	Vitamin B deficiency (E53)	130/130	UKBB
Obesity (E66)	1481/1481	UKBB	Hemiplegia (G81)	111/111	UKBB
Lipoprotein metabolism disorder (E78)	3880/3880	UKBB	Facial nerve disorders (G51)	95/95	UKBB
Mineral metabolism disorder (E83)	291/291	UKBB	Tower rearranging (21004)	8412	UKBB
Volume depletion	240/240	UKBB	Matrix pattern (6373)	8501	UKBB
Delirium	92/92	UKBB	TMT-A (6348)	8599	UKBB
Alcohol abuse	341/341	UKBB	TMT-B (6350)	8599	UKBB
Tobacco abuse	863/863	UKBB	DSST (23324)	8523	UKBB
Bipolar affective disorder	77/77	UKBB	Pairs matching (399)	20945	UKBB
Phobic anxiety disorder	84/84	UKBB	Numerical memory (4282)	9323	UKBB
Multiple sclerosis	109/109	UKBB	Prospective memory (4288)	19681	UKBB
Epilepsy	250/250	UKBB	Reaction time (20023)	21258	UKBB
Migraine	508/508	UKBB	Fluid intelligence (20016)	19184	UKBB
Sleep disorders	590/590	UKBB			

1400 eTable 3: Comparison of variants identified via MuSIC with other studies. Using the AAL 1401 atlas, we found (using the same data in the current study) that 269 independent significant SNPs 1402 had 356 pairwise associations with 54 AAL brain regions. 230 out of the 269 SNPs matched with 1403 the SNPs in MuSIC. Among the 39 unmatched SNPs, 15 SNPs were in linkage disequilibrium (LD, $r^2 > 0.6$) with MuSIC SNPs (Supplementary eFile 5). As a second example, Zhao et al.⁴ 1404 1405 reported that 251 independent significant SNPs had 346 pairwise associations with 43 GM regions using the Mindboggle atlas on the UKBB (N=19,629).⁸² 129 of the 251 SNPs matched with SNPs 1406 1407 identified by MuSIC. Among these non-matching SNPs (127), 31 were in LD with MuSIC SNPs 1408 (Supplementary eFile 6). Similarly, Elliot et al.⁵ (N=8428) discovered that 20 independent 1409 significant SNPs had 58 pairwise associations with 52 GM regions from atlases in Freesurfer and 1410 FSL software. Out of the 20 SNPs, 16 coincided with MuSIC SNPs. Among the four unmatched 1411 SNPs, 1 SNP was in LD with MuSIC SNPs (Supplementary eFile 7). Note that the definition of 1412 independent significant SNPs or genomic loci might slightly differ between studies.

	Study/Atlas	Identified genomic loci	Matched loci	Loci in LD	Novel loci	Database	Sample size	Ancestry
-	MuSIC	915	NA	NA	NA	UKBB	18,052	European
	AAL	218	162	13	740	UKBB	18,052	European
	Zhao et al.4	251	73	14	828	UKBB	19,629	European
	Elliot et al. ⁵	20	16	1	898	UKBB	8428	European
_	GWAS Catalog	NA	298	NA	617	NA	NA	NA
_	Zhao et al. ⁴ Elliot et al. ⁵ GWAS Catalog	251 20 NA	73 16 298	14 1 NA	828 898 617	UKBB UKBB NA	19,629 8428 NA	Europea Europea NA

eTable 4: Classification balanced accuracy for disease classification and effect size of these

1416 imaging signatures.

1417 Disease classification performance is presented using balanced accuracy. The mean and standard

- 1418 deviation are presented. Cohen's d was computed to compare the SPARE scores between groups.
- 1419 Multi-scale classification^a: All 2003 PSCs from multiple scales were fit into the classifier.
- 1420 Multi-scale classification^b: PSCs from all scales were fit into the classifier with a nested feature
- 1421 selection procedure (SVM-REF). The motivation is that PSCs from different scales are
- 1422 hierarchical and correlated. The nested feature selection can select the features most relevant to
- 1423 the specific task. We avoided any statistical comparison of the performance of machine learning
- 1424 models because available statistical tests are liberal and often lead to false-positive conclusions
- 1425 due to the complexity of the cross-validation procedure.⁸³

a). Classification results for an subjects in an sites using a nested C v procedure														
PSC	AD	d	MCI	d	SCZ	d	DM	d	HTN	d	MDD	d	ASD	d
C32	0.78 <u>+</u> 0.02	1.52	0.62 ± 0.02	0.59	0.55 ± 0.02	0.30	0.56 ± 0.02	0.35	0.55 ± 0.02	0.28	0.52 ± 0.02	0.16	0.50 ± 0.02	0.07
C64	0.81 ± 0.02	1.73	0.63 ± 0.02	0.66	0.57 ± 0.02	0.41	0.57 ± 0.02	0.40	0.56 <u>+</u> 0.02	0.31	0.53 ± 0.02	0.17	0.53 ± 0.02	0.19
C128	0.82 ± 0.02	1.82	0.65 ± 0.02	0.76	0.59 ± 0.02	0.47	0.56 ± 0.02	0.33	0.55 ± 0.02	0.30	0.52 ± 0.02	0.15	0.52 ± 0.02	0.15
C256	0.85 ± 0.02	2.08	0.66 ± 0.02	0.91	0.59 ± 0.02	0.50	0.56 ± 0.02	0.47	0.54 ± 0.02	0.31	0.51 ± 0.02	0.13	0.52 ± 0.02	0.16
C512	0.88 ± 0.02	2.34	0.67 ± 0.02	1.06	0.62 ± 0.02	0.62	0.57 ± 0.02	0.54	0.56 <u>+</u> 0.02	0.42	0.52 ± 0.02	0.05	0.54 ± 0.02	0.24
C1024	0.90 ± 0.02	2.50	0.72 ± 0.02	1.12	0.65 ± 0.02	0.75	0.60 ± 0.02	0.59	0.59 <u>+</u> 0.02	0.46	0.56 ± 0.02	0.13	0.55 ± 0.02	0.29
Multi- scale ^a	0.91 ± 0.02	2.54	0.72 ± 0.02	1.12	0.66 ± 0.02	0.77	0.61 ± 0.02	0.64	0.59 <u>+</u> 0.02	0.47	0.55 ± 0.02	0.23	0.56 ± 0.02	0.30
Multi- scale ^b	0.92 ± 0.02	2.61	0.73 ± 0.02	1.13	0.67 ± 0.02	0.78	0.64 ± 0.02	0.67	0.61 ± 0.02	0.49	0.55 ± 0.02	0.26	0.58 ± 0.02	0.32
AAL	0.82 ± 0.02	1.81	0.66 <u>±</u> 0.02	0.75	0.59 ± 0.02	0.46	0.57 ± 0.02	0.32	0.57 ± 0.02	0.35	0.52 ± 0.02	0.08	0.52 ± 0.02	0.14
RAVENS	0.85 ± 0.02	2.04	0.64 ± 0.02	0.74	0.60 ± 0.02	0.45	0.58 <u>+</u> 0.02	0.33	0.55 <u>+</u> 0.02	0.34	0.50 ± 0.02	0.05	0.54 ± 0.02	0.15

1426 a): Classification results for all subjects in all sites using a nested CV procedure

1427

1428	b): The classification results of the balanced accuracy (BA) from the test data in the nested CV
1429	and the independently left-out site for the task of AD vs. CN were assessed using all available
1430	multi-scale PSCs ^a . Three sites, namely ADNI, AIBL, and PENN, were considered for this
1431	analysis. However, UKBB, BIOCARD, and BLSA data were excluded due to limited AD cases
1432	(eTable 1). Similarly, data from OASIS were excluded due to discrepancies in the diagnosis
1433	criteria for AD, as previously stated in our previous work ³⁶ .

Left-out site	Test BA in CV	Test BA in the left-out site
ADNI	0.90 ± 0.02	0.88 ± 0.02
AIBL	0.88 ± 0.02	0.95±0.02
PENN	0.90 ± 0.02	0.95±0.02

eTable 5: 119 MUSE gray matter regions of interest. L: Left hemisphere: R: Right hemisphere: ROI: region of interest.

L. Lett heinisphere, K. Kig	giù nennsphere, KOI. legion of interest.	
MUSE ROI	MUSE ROI	MUSE ROI
Precentral gyrus (R)	Occipital fusiform gyrus (R)	Anterior insula (L)
Precentral gyrus (L)	Planum temporale (R)	Anterior orbital gyrus (R)
Accumbens area (R)	Cerebellar vermal lobules I-V	Anterior orbital gyrus (L)
Accumbens area (L)	Cerebellar vermal lobules VI-VII	Angular gyrus (R)
Amygdala (R)	Cerebellar vermal lobules VIII-X	Angular gyrus (L)
Amygdala (L)	Basal forebrain (R)	Calcarine cortex (R)
Occipital pole (L)	Basal forebrain (L)	Calcarine cortex (L)
Caudate (R)	Middle temporal gyrus (L)	Central operculum (R)
Caudate (L)	Occipital pole (R)	Central operculum (L)
Cerebellum exterior (R)	Planum temporale (L)	Cuneus (R)
Cerebellum exterior (L)	Parietal operculum (L)	Cuneus (L)
Planum polare (L)	Postcentral gyrus (R)	Entorhinal area (R)
Middle temporal gyrus (R)	Postcentral gyrus (L)	Entorhinal area (L)
Hippocampus (R)	Posterior orbital gyrus (R)	Frontal operculum (R)
Hippocampus (L)	Temporal pole (R)	Frontal operculum (L)
Precentral gyrus medial	• • • • •	
segment (R)	Temporal pole (L)	Frontal pole (R)
Precentral gyrus medial	Triangular part of the inferior frontal gyrus	- · · ·
segment (L)	(R)	Frontal pole (L)
Superior frontal gyrus	Triangular part of the inferior frontal gyrus	
medial segment (R)	(L)	Fusiform gyrus (R)
Superior frontal gyrus		
medial segment (L)	Transverse temporal gyrus (R)	Fusiform gyrus (L)
Pallidum (R)	Superior frontal gyrus medial segment (L)	Gyrus rectus (R)
Pallidum (L)	Planum polare (R)	Gyrus rectus (L)
Putamen (R)	Transverse temporal gyrus (L)	Inferior occipital gyrus (R)
Putamen (L)	Anterior cingulate gyrus (R)	Inferior occipital gyrus (L)
Thalamus proper (R)	Anterior cingulate gyrus (L)	Inferior temporal gyrus (R)
Thalamus proper (L)	Anterior insula (R)	Inferior temporal gyrus (L)
Lingual gyrus (R)	Occipital fusiform gyrus (L)	Subcallosal area (R)
Lingual gyrus (L)	Opercular part of inferior frontal gyrus (R)	Subcallosal area (L)
Lateral orbital gyrus (R)	Opercular part of inferior frontal gyrus (L)	Superior frontal gyrus (R)
Lateral orbital gyrus (L)	Orbital part of inferior frontal gyrus (R)	Superior frontal gyrus (L)
Middle cingulate gyrus (R)	Orbital part of inferior frontal gyrus (L)	Supplementary motor cortex (R)
Middle cingulate gyrus (L)	Posterior cingulate gyrus (R)	Supplementary motor cortex (L)
Medial frontal cortex (R)	Posterior cingulate gyrus (L)	Supramarginal gyrus (R)
Medial frontal cortex (L)	Precuneus (R)	Supramarginal gyrus (L)
Middle frontal gyrus (R)	Precuneus (L)	Superior occipital gyrus (R)
Middle frontal gyrus (L)	Parahippocampal gyrus (R)	Superior occipital gyrus (L)
Middle occipital gyrus (R)	Parahippocampal gyrus (L)	Superior parietal lobule (R)
Middle occipital gyrus (L)	Posterior insula (R)	Superior parietal lobule (L)
Medial orbital gyrus (R)	Posterior insula (L)	Superior temporal gyrus (R)
Medial orbital gyrus (L)	Parietal operculum (R)	Superior temporal gyrus (L)
Superior frontal gyrus		
medial segment (R)	Posterior orbital gyrus (L)	

1438

eAlgorithm 1: Algorithm for sopNMF.

- 1439 The source code of the Python implementation of sopNMF is available here:
- 1440 <u>https://github.com/anbai106/SOPNMF</u>

Algorithm 1: sopNMF

• **Input**:maximum number of epochs e, number of component C or r, batch size b, early stopping criteria θ (i.e., the loss without decreasing for a certain epochs);

```
• Output: W \in \mathbb{R}^{d \times r}, H \in \mathbb{R}^{r \times n};
```

• Initialization: W ;

```
if not \theta or epoch \neq e then
```

```
for p \leftarrow 0 to e do
            for i \leftarrow 0 to t do
                   Read mini-batch X_{bi}
                   Update W_{i+1} via Eq. 2
            \mathbf{end}
            loss = \sum_{i=1}^{\left\lceil \frac{n}{b} \right\rceil} \| \boldsymbol{X}_{bi} - \boldsymbol{W} \boldsymbol{W}^T \boldsymbol{X}_{bi} \|_F^2 (Eq.3)
            if loss in \theta then
                   Stop
            else
                   Shuffle X
                   Continue
            \mathbf{end}
      end
else
     Stop
end
```

1442 1443

1444 **References**

- 1445
- 1446 1. Kuhn, H. W. The Hungarian method for the assignment problem. *Naval Research Logistics*
- 1447 *Quarterly* **2**, 83–97 (1955).
- 1448 2. Pomponio, R. *et al.* Harmonization of large MRI datasets for the analysis of brain imaging

1449 patterns throughout the lifespan. *Neuroimage* **208**, 116450 (2020).

- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
 annotation of genetic associations with FUMA. *Nat Commun* 8, 1826 (2017).
- 1452 4. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
- 1453 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 1454 5. Samper-González, J. et al. Reproducible evaluation of classification methods in
- 1455 Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* 183,
- 1456 504–521 (2018).
- 1457 6. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer's disease:
- 1458 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 1459 7. Wen, J. *et al.* Reproducible Evaluation of Diffusion MRI Features for Automatic
- 1460 Classification of Patients with Alzheimer's Disease. *Neuroinformatics* **19**, 57–78 (2021).
- 1461 8. Stasinopoulos, D. M. & Rigby, R. A. Generalized Additive Models for Location Scale and
 1462 Shape (GAMLSS) in R. *Journal of Statistical Software* 23, 1–46 (2008).
- 1463 9. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- 1464 Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry
- 1465 (2022) doi:10.1001/jamapsychiatry.2022.0020.

- 1466 10. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants
- 1467 influencing regional brain volumes and refines their genetic co-architecture with cognitive
- 1468 and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).
- 1469 11. Klein, A. & Tourville, J. 101 Labeled Brain Images and a Consistent Human Cortical
- 1470 Labeling Protocol. *Frontiers in Neuroscience* **6**, 171 (2012).
- 1471 12. Elliott, L. T. et al. Genome-wide association studies of brain imaging phenotypes in UK
- 1472 Biobank. *Nature* **562**, 210–216 (2018).
- 1473 13. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. in Advances in Neural
- 1474 Information Processing Systems 12 (eds. Solla, S. A., Leen, T. K. & Müller, K.) 307–313
- 1475 (MIT Press, 2000).